Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose (Review)

Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, De Grauw WJC

**THE COCHRANE
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2009, Issue 1

<http://www.thecochranelibrary.com>

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	2
OBJECTIVES	3
METHODS	3
RESULTS	7
Figure 1.	8
DISCUSSION	12
AUTHORS' CONCLUSIONS	14
ACKNOWLEDGEMENTS	14
REFERENCES	15
CHARACTERISTICS OF STUDIES	18
DATA AND ANALYSES	26
Analysis 1.1. Comparison 1 Acarbose versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus.	29
Analysis 1.2. Comparison 1 Acarbose versus placebo, Outcome 2 Occurrence of death (total).	30
Analysis 1.3. Comparison 1 Acarbose versus placebo, Outcome 3 Occurrence of cardiovascular death.	30
Analysis 1.4. Comparison 1 Acarbose versus placebo, Outcome 4 Occurrence of cardiovascular disease (any).	31
Analysis 1.5. Comparison 1 Acarbose versus placebo, Outcome 5 Occurrence of myocardial infarctions.	31
Analysis 1.6. Comparison 1 Acarbose versus placebo, Outcome 6 Occurrence of angina pectoris.	32
Analysis 1.7. Comparison 1 Acarbose versus placebo, Outcome 7 Occurrence of revascularisation procedures.	32
Analysis 1.8. Comparison 1 Acarbose versus placebo, Outcome 8 Occurrence of congestive heart failure.	33
Analysis 1.9. Comparison 1 Acarbose versus placebo, Outcome 9 Occurrence of cerebrovascular events.	33
Analysis 1.10. Comparison 1 Acarbose versus placebo, Outcome 10 Occurrence of peripheral vascular events.	34
Analysis 1.11. Comparison 1 Acarbose versus placebo, Outcome 11 Change in glycated haemoglobin (%).	34
Analysis 1.12. Comparison 1 Acarbose versus placebo, Outcome 12 Change in fasting blood glucose (mmol/l).	35
Analysis 1.13. Comparison 1 Acarbose versus placebo, Outcome 13 Change in post-load blood glucose (mmol/l).	35
Analysis 1.14. Comparison 1 Acarbose versus placebo, Outcome 14 Change in total cholesterol (mmol/l).	36
Analysis 1.15. Comparison 1 Acarbose versus placebo, Outcome 15 Change in HDL-cholesterol (mmol/l).	36
Analysis 1.16. Comparison 1 Acarbose versus placebo, Outcome 16 Change in LDL-cholesterol (mmol/l).	37
Analysis 1.17. Comparison 1 Acarbose versus placebo, Outcome 17 Change in triglycerides (mmol/l).	37
Analysis 1.18. Comparison 1 Acarbose versus placebo, Outcome 18 Change in fasting insulin levels (pmol/l).	38
Analysis 1.19. Comparison 1 Acarbose versus placebo, Outcome 19 Change in post-load insulin levels (pmol/l).	38
Analysis 1.20. Comparison 1 Acarbose versus placebo, Outcome 20 Change in body weight (Kg).	39
Analysis 1.21. Comparison 1 Acarbose versus placebo, Outcome 21 Change in body mass index (Kg/m2).	39
Analysis 1.22. Comparison 1 Acarbose versus placebo, Outcome 22 Change in diastolic blood pressure (mmHg).	40
Analysis 1.23. Comparison 1 Acarbose versus placebo, Outcome 23 Change in systolic blood pressure (mmHg).	40
Analysis 1.24. Comparison 1 Acarbose versus placebo, Outcome 24 Occurrence of side effects (total).	41
Analysis 1.25. Comparison 1 Acarbose versus placebo, Outcome 25 Occurrence of gastro-intestinal side-effects.	41
Analysis 2.1. Comparison 2 Acarbose versus metformin, Outcome 1 Incidence of type 2 diabetes mellitus.	42
Analysis 2.2. Comparison 2 Acarbose versus metformin, Outcome 2 Change in fasting blood glucose (mmol/l).	42
Analysis 2.3. Comparison 2 Acarbose versus metformin, Outcome 3 Change in post-load blood glucose (mmol/l).	43
Analysis 2.4. Comparison 2 Acarbose versus metformin, Outcome 4 Change in total cholesterol (mmol/l).	43
Analysis 2.5. Comparison 2 Acarbose versus metformin, Outcome 5 Change in triglycerides (mmol/l).	44
Analysis 2.6. Comparison 2 Acarbose versus metformin, Outcome 6 Change in body mass index (Kg/m2).	44
Analysis 2.7. Comparison 2 Acarbose versus metformin, Outcome 7 Change in diastolic blood pressure (mmHg).	45
Analysis 2.8. Comparison 2 Acarbose versus metformin, Outcome 8 Change in systolic blood pressure (mmHg).	45
Analysis 3.1. Comparison 3 Acarbose versus diet and exercise, Outcome 1 Incidence of type 2 diabetes mellitus.	46
Analysis 3.2. Comparison 3 Acarbose versus diet and exercise, Outcome 2 Change in fasting blood glucose (mmol/l).	46
Analysis 3.3. Comparison 3 Acarbose versus diet and exercise, Outcome 3 Change in post-load blood glucose (mmol/l).	47
Analysis 3.4. Comparison 3 Acarbose versus diet and exercise, Outcome 4 Change in total cholesterol (mmol/l).	47

Analysis 3.5. Comparison 3 Acarbose versus diet and exercise, Outcome 5 Change in triglycerides (mmol/l). . . .	48
Analysis 3.6. Comparison 3 Acarbose versus diet and exercise, Outcome 6 Change in body mass index (Kg/m2). . .	48
Analysis 3.7. Comparison 3 Acarbose versus diet and exercise, Outcome 7 Change in diastolic blood pressure (mmHg). . .	49
Analysis 3.8. Comparison 3 Acarbose versus diet and exercise, Outcome 8 Change in systolic blood pressure (mmHg). . .	49
Analysis 4.1. Comparison 4 Acarbose versus no treatment, Outcome 1 Incidence of type 2 diabetes mellitus. . . .	50
Analysis 4.2. Comparison 4 Acarbose versus no treatment, Outcome 2 Change in fasting blood glucose (mmol/l). . .	50
Analysis 4.3. Comparison 4 Acarbose versus no treatment, Outcome 3 Change in post-load blood glucose (mmol/l). . .	51
Analysis 4.4. Comparison 4 Acarbose versus no treatment, Outcome 4 Change in total cholesterol (mmol/l). . . .	51
Analysis 4.5. Comparison 4 Acarbose versus no treatment, Outcome 5 Change in triglycerides (mmol/l).	52
Analysis 4.6. Comparison 4 Acarbose versus no treatment, Outcome 6 Change in body mass index (Kg/m2). . . .	52
Analysis 4.7. Comparison 4 Acarbose versus no treatment, Outcome 7 Change in diastolic blood pressure (mmHg). . .	53
Analysis 4.8. Comparison 4 Acarbose versus no treatment, Outcome 8 Change in systolic blood pressure (mmHg). . .	53
Analysis 4.9. Comparison 4 Acarbose versus no treatment, Outcome 9 Occurrence of side effects (total).	54
Analysis 4.10. Comparison 4 Acarbose versus no treatment, Outcome 10 Occurrence of gastro-intestinal side-effects. . .	54
ADDITIONAL TABLES	54
APPENDICES	55
WHAT'S NEW	63
HISTORY	64
CONTRIBUTIONS OF AUTHORS	64
DECLARATIONS OF INTEREST	64
SOURCES OF SUPPORT	64
INDEX TERMS	65

[Intervention Review]

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Floris A Van de Laar¹, Peter LBJ Lucassen², Reinier P Akkermans³, Eloy H Van de Lisdonk⁴, Wim JC De Grauw³

¹Department of General Practice, 117 HAG, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. ²Department of General Practice and Family Medicine, Radboud University Medical Centre, Nijmegen, Netherlands. ³Department of General Practice, 117 HAG, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. ⁴Department of General Practice and Family Medicine, Radboud University Medical Centre, Nijmegen, Netherlands

Contact address: Floris A Van de Laar, Department of General Practice, 117 HAG, Radboud University Nijmegen Medical Centre, P.O. Box 9101, Nijmegen, 6500 HB, Netherlands. f.vandelaar@cochraneprimarycare.org f.vandelaar@hag.umcn.nl.

Editorial group: Cochrane Metabolic and Endocrine Disorders Group.

Publication status and date: Edited (no change to conclusions), published in Issue 1, 2009.

Review content assessed as up-to-date: 27 February 2006.

Citation: Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, De Grauw WJC. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD005061. DOI: 10.1002/14651858.CD005061.pub2.

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Alpha-glucosidase inhibitors (AGIs) reduce blood glucose levels and may thus prevent type 2 diabetes and cardiovascular disease in patients with impaired glucose tolerance (IGT). These possible effects, and the effects on quality of life, plasma lipids and body weight, have never been investigated in a systematic literature review and meta-analysis.

Objectives

To assess the effects of alpha-glucosidase inhibitors in patients IGT or impaired fasting blood glucose (IFBG), or both.

Search methods

We searched *The Cochrane Library*, PUBMED, EMBASE, Web of Science, LILACS, databases of ongoing trials, reference lists of relevant reviews, and we contacted experts and manufacturers.

Selection criteria

Randomised controlled trials of at least one-year duration in patients with IGT or IFBG, or both, comparing AGI monotherapy with any other intervention.

Data collection and analysis

Two reviewers read all abstracts, assessed quality and extracted data independently. Discrepancies were resolved by consensus or by the judgement of a third reviewer.

Main results

We included five trials (2360 participants), all investigating acarbose, that included patients with IGT or patients 'at increased risk for diabetes' (n = 1). Study duration was one, three (n = 2), five and six years. One study was at low risk of bias and four studies at high risk of bias. Except for the outcome incidence of type 2 diabetes in acarbose versus no treatment (two studies), meta-analyses were

not possible. Data from the study at low risk of bias suggests that acarbose decreases the occurrence of type 2 diabetes (NNT = 10), cardiovascular events (NNT = 50, based on 47 events, study not initially powered for this outcome), post-load blood glucose (-0.6 mmol/L, 95% CI -1.0 to -0.3) and body mass index (0.3 kg/m², 95% CI -0.1 to -0.5). No statistically significant effects were observed on mortality, other morbidity, glycated haemoglobin, fasting blood glucose, lipids and blood pressure. The effects on the incidence of type 2 diabetes were confirmed in two studies at high risk of bias (OR 0.2, 95% CI 0.1 to 0.6). Adverse effects were mostly of gastro-intestinal origin (OR 3.5, 95% CI 2.7 to 4.4).

Authors' conclusions

There is evidence that acarbose reduces the incidence of type 2 diabetes in patients with IGT. However, it is unclear whether this should be seen as prevention, delay or masking of diabetes. Acarbose may prevent the occurrence of cardiovascular events, but this finding needs to be confirmed in more studies.

PLAIN LANGUAGE SUMMARY

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Alpha-glucosidase inhibitors (acarbose, miglitol, voglibose) are drugs that delay the breakdown of carbohydrates in the gut, and consequently slow down the absorption of sugars. Patients with type 2 diabetes may use it therapeutically. People with a raised blood glucose level (without being a diabetes patient) may use this drug in order to prevent developing type 2 diabetes and diabetes related morbidity such as cardiovascular diseases. To find evidence for these assumptions, we searched the medical literature for randomised controlled trials of at least one-year duration, investigating alpha-glucosidase inhibitors for patients with impaired glucose tolerance (IGT) or impaired fasting blood glucose (IFBG). Patients with IGT or IFBG have raised blood glucose levels, but do not meet the criteria for having type 1 or type 2 diabetes.

In our review we included five studies, representing 2360 participants, investigating acarbose. Of these studies, one was of high quality, and two did not show exact data, as the results were not available in full publication. The study of high quality yielded that if 10 people with IGT would take acarbose for three years, one case of diabetes would not occur. This finding was confirmed in studies of lower quality. The relevance of this finding is questionable because we found only small effects on blood glucose levels, and the mechanism behind this finding remains unclear: does acarbose really prevent diabetes does it delay the occurrence or mask type 2 diabetes? With respect to the effect on the occurrence of cardiovascular diseases, a dubious preventive effect of acarbose on the occurrence of myocardial infarctions was found. However, definitive conclusion could not be drawn and this latter finding should be confirmed in other studies. We found no statistically significant effects on the occurrence of death, other complications related to IGT, or quality of life. Side effects were mostly of gastro-intestinal origin (flatulence, diarrhoea).

The low number of studies, the poor quality of four of the included studies, and the missing data of two included studies limited this review. First, the missing data of two included studies need to be made available for a future update of this review. Next, the results of the two ongoing studies should be implemented in the review. If, after that, the evidence remains inconclusive, new trials should be initiated in order to investigate the true value of alpha-glucosidase inhibitors for patients with impaired glucose tolerance or impaired fasting blood glucose.

BACKGROUND

Description of the condition

Impaired glucose tolerance (IGT) and impaired fasting blood glucose (IFBG) are generally recognised as an expression of abnormal glucose homeostasis that is not severe enough to meet the crite-

ria for type 2 diabetes mellitus. The term IGT was introduced in 1979. In the past IGT has been called a 'pre-state' of diabetes or 'prediabetes' (NDDG 1979). The term IFBG (sometimes referred to as impaired fasting glycaemia) has been introduced much later (ADA 1997). IGT and IFBG represent different pathophysiological mechanisms: IGT is seen as a characteristic of peripheral in-

sulin resistance and IFBG is seen as an expression of raised hepatic glucose output and a defect in early insulin secretion. On the other hand, there are many similarities, as both IGT and IFBG are associated with an increased risk of diabetes and the development of (diabetes related) complications such as cardiovascular disease (Unwin 2002). Currently, the criteria for IGT and IFBG are as follows (plasma venous glucose concentrations):

- IGT - fasting blood glucose less than 7.0 mmol/L and two-hour post-load blood glucose 7.8 to 11.0 mmol/L;
- IFBG - fasting blood glucose 6.1 to 6.9 mmol/L (two-hour post-load blood glucose less than 7.8 mmol/L, if measured) (ADA 1999; WHO 1999). In 2003, the ADA recommended to change these criteria to 5.6 to 6.9 mmol/L (ADA 2003)

IGT and IFBG cause no symptoms and the condition should be seen as a risk factor more than a disease itself. It is closely related to other risk factors of type 2 diabetes such as obesity and overweight, unfavourable dietary habits and a shortage of exercise. People with IGT or IFBG are at increased risk of developing type 2 diabetes and cardiovascular disease (even before the onset of diabetes). Thus, the question arises whether an intervention in patients with IGT or IFBG could prevent the development of type 2 diabetes and cardiovascular complications. Life-style interventions consisting of exercise or diet, or both, showed that the incidence of diabetes might be reduced (relative risk reduction) in up to 58% of cases (Pan 1997; Tuomilehto 2001; Knowler 2002). In addition, pharmacological interventions have been investigated in patients with IGT. Especially drugs that claim to intervene with insulin resistance seem appropriate: biguanides (metformin: decreases hepatic glucose output and increases insulin action) (Knowler 2002), thiazolidinediones (rosiglitazone, pioglitazone: increase insulin sensitivity by increasing glucose utilization in muscle and liver) (Buchanan 2002) and alpha-glucosidase inhibitors (see further).

Description of the intervention

Alpha-glucosidase inhibitors (AGIs) are reversible inhibitors of alpha-glucosidase, an enzyme present in the brush border of the small intestine. Currently, three AGIs exist: acarbose, miglitol and voglibose. Emiglitate, a fourth AGI, is currently not available on the market. AGIs delay absorption of complex carbohydrates and thus inhibit postprandial glucose peaks and consequently lower postprandial insulin levels. In the treatment of type 2 diabetes, AGIs have been proven to have beneficial effects on glycaemic control and post-load insulin levels but there is no evidence for a reduction of mortality or morbidity (Van de Laar 2005).

Potential side-effects are of special importance in the use of medication in persons with IGT or IFBG for two reasons. First, IGT and IFBG are asymptomatic, so people will, in contrast to potential side-effects, not notice any direct benefits from the medication. Second, because of the chronic and long-lasting character of

IGT and IFBG, medication will have to be used for a long period of time. Therefore, long-term safety is very important. AGIs cause unfavourable dose-dependent side-effects, mostly flatulence and other gastro-intestinal side-effects, when compared to placebo or sulphonylurea. But there is no evidence for long-term detrimental effects of AGIs (Van de Laar 2005).

Why it is important to do this review

More recently, AGIs have been put into a new light as a result of a study on the efficacy of acarbose in patients with IGT (Chiasson 2002; Chiasson 2003). This study showed that acarbose could prevent or delay the development of IGT into type 2 diabetes. Moreover, it showed a reduced risk of cardiovascular disease and hypertension in the acarbose treated group. However, the conclusions of this study are heavily debated (Chiasson 2004; Kaiser 2004; Sawicki 2004). We have found no systematic review that focuses exclusively on the efficacy of AGIs for patients with IGT or IFBG.

OBJECTIVES

To assess the effects of alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials with a minimum duration of one year. Because the common adverse effects of AGIs make true blinding difficult, both blinded and non-blinded studies were included. Studies published in any language and all identified trials, published or unpublished, were investigated.

Types of participants

Patients referred to as having a prediabetic state, that is IGT or IFBG, or both, existing or newly diagnosed. Changes in diagnostic criteria, both for IGT or IFBG, or both, or diabetes mellitus type 2 (ADA 1997; ADA 1999; NDDG 1979; Unwin 2002; WHO 1980; WHO 1985; WHO 1999) may have produced variability in the clinical characteristics of the patients included as well as in the results obtained. We planned to explore these differences in a sensitivity analysis.

Types of interventions

Monotherapy with AGIs (acarbose, miglitol or voglibose) compared with:

- placebo;
- a non-pharmacological intervention (for example: diet therapy, exercise);
- biguanides (for example, metformin);
- thiazolidinediones (for example, pioglitazone);
- sulphonylurea (for example, glibenclamide);
- meglitinide (for example, nateglinide);
- any other pharmacological intervention.

Types of outcome measures

Primary outcomes

- incidence of type 2 diabetes mellitus: diagnosed with criteria prevailing at the time of the diagnosis ([ADA 1997](#); [ADA 1999](#); [NDDG 1979](#); [WHO 1980](#); [WHO 1985](#); [WHO 1998](#));
- morbidity related to impaired glucose metabolism, the metabolic syndrome or type 2 diabetes: vascular complications (angina pectoris, myocardial infarction, stroke, peripheral vascular disease, amputation), neuropathy, retinopathy, nephropathy, erectile dysfunction, and hyperosmolar nonketotic dysregulation;
- mortality: total mortality, mortality related to impaired glucose metabolism, the metabolic syndrome or type 2 diabetes (death from myocardial infarction, stroke, renal disease, or sudden death, death from hyperosmolar nonketotic coma);

Secondary outcomes

- glycaemic control: glycated haemoglobin levels, fasting and post-load blood glucose levels;
- plasma lipids (triglycerides, total-, high-density lipoprotein (HDL)- and low-density lipoprotein (LDL)-cholesterol);
- blood pressure: diastolic and systolic blood pressure;
- fasting and post-load insulin and C-peptide levels;
- body weight (or body mass index);
- adverse effects (for example diarrhoea, stomachache, flatulence);
- quality of life, assessed with a validated instrument;
- costs.

Specific patient covariates, effect modifiers, confounders

- Compliance.

Timing of outcome assessment (length of intervention)

We assessed a possible influence of treatment duration in a sensitivity analysis.

Search methods for identification of studies

Electronic searches

We used the following sources for the identification of trials:

- *The Cochrane Library* (2006, Issue 1);
- PUBMED (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>) (contains MEDLINE and a number of additional life science journals, 1966 to February 2006);
- EMBASE (1974 to October 2005);
- LILACS (www.bireme.br/bvs/l/ibd.htm) from 1986 to March 2006;
- Web of Science (contains: Science Citation Index Expanded 1945 to February 2006; Social Sciences Citation Index 1956 to February 2006; Arts & Humanities Citation Index 1975 to February 2006).

We also searched databases of ongoing trials (latest access March 2006): Current Controlled Trials (<http://www.controlled-trials.com> - with links to other databases of ongoing trials); UK National Research Register (<http://www.update-software.com/National/nrr-frame.html>); USA - CenterWatch Clinical Trials Listing Service (<http://www.CenterWatch.com/>); USA - National Institutes of Health (<http://clinicalstudies.info.nih.gov/>); Dutch Trial Register (Nederlands Trial Register) (<http://www.trialregister.nl/>). The described search strategy (see [Appendix 1](#)) was used for PUBMED. For use with EMBASE and Web of Science the strategy was slightly adapted because these databases have different interfaces. The necessary changes in the search string were done in such a way that the search became more sensitive (that is yields a higher number of 'hits'). In *The Cochrane Library*, LILACS and the databases of ongoing trials we searched with the various text words for the AGIs and their brand names.

We combined three different search strategies (specified in [Appendix 1](#)):

- for alpha-glucosidase inhibitors we used a strategy used for a recent systematic review on AGIs ([Van de Laar 2005](#));
- controlled trials we used a sensitive validated search strategy ([Robinson 2002](#));
- for IGT and IFBG we developed a search strategy combining keywords (MeSH headings) and text words. We extensively tested it by running the search and subsequently investigated whether known key-studies were not included, we then adjusted the model until we didn't find any relevant study that was not found by the search string.

Searching other resources

Authors of relevant identified studies and other experts were contacted by mail in order to obtain additional references, unpublished trials, and ongoing trials or to obtain missing data not reported in the original trials. Similarly, manufacturers and patent holders (Bayer AG, Sanofi-Synthelabo, Pfizer, Takeda) were contacted in order to retrieve information on AGIs trials, published and unpublished.

We searched reference lists of relevant trials and AGI reviews and selected possible references that were already in our own files.

Data collection and analysis

Selection of studies

Two reviewers (FVDL and PL) independently checked the titles, abstract sections and keywords of every record retrieved. Full articles were retrieved for further assessment when the information given suggested that the study:

- included patients with IGT or IFBG;
- compared AGIs with placebo or any other control;
- assessed one or more relevant predefined clinical outcomes;
- used random allocation to the comparison groups.

In case of any doubt regarding these criteria from the information given by the title and abstract, the full article was retrieved for clarification. Interrater agreement for study selection was assessed using the kappa statistic (Cohen 1960). A third party (EVDL) resolved differences in opinions between the two reviewers. If resolving disagreement was not possible, the article was added to those 'awaiting assessment' and the authors were contacted for clarification. If no clarification was provided, we planned to consult the review group editorial base.

Data extraction and management

Two reviewers extracted data on intervention and outcomes independently, using a pre-tested data extraction form that was adapted from a standard form provided by the review group. The data extraction form included the following items:

- **General information:** author, type of publication (including the existence of duplicate or multiple publications), year of publication, language, country where the study was conducted, setting (general practice, hospital or outpatient/rural, city, developed/developing world/single or multi-centre), the stated aim of the study published, sponsor(s), ethics approval;
- **Study characteristics:** parallel or cross-over, type of control groups (placebo, other medication etc.), existence of run-in or wash-out period, or both, description of possible carry-over effect (for cross-over studies), method, type and quality of randomisation, method and quality of allocation concealment,

method and quality of blinding, information about handling of drop-outs, withdrawals and losses to follow-up, numbers of and reasons for drop-out, method and quality of blinding of outcome assessment (if applicable), method and quality of blinding of analyses, existence of possible sub-groups, method of assessment of compliance;

- **Participants:** description of diagnostic criteria for IGT or IFBG, or both, and diabetes mellitus type 2, inclusion and exclusion criteria;

- **Interventions:** specification of possible life-style co-intervention, the nature, dose and regimen of AGI(s) and control interventions, duration of intervention and follow-up;

- **Baseline characteristics and measurements:** numbers of patients, sex, age, ethnicity, socio-economic status and duration of diabetes, other risk factors for type 2 diabetes or macrovascular disease (familiar disposition, history of gestational diabetes, exercise, smoking) existence of significant differences at baseline, baseline glycated haemoglobin, fasting and post-load blood glucose, plasma lipids (triglycerides, total-, HDL- and LDL-cholesterol), height, weight and body mass index (BMI), fasting and post-load insulin and C-peptide (standard deviations if applicable), specifications (including reference ranges) of all laboratory measurements, type of post-load test, time between fasting and post-load measurements, centralisation of laboratory measurements, assessment of health-status, definitions of health outcomes (for example myocardial infarction, heart failure, renal failure);

- **Outcomes:** total and disease specific deaths and morbidity, quality of life (including method of assessment), mean changes (standard deviation, SD) of the following values: glycated haemoglobin, fasting and post-load blood glucose, lipids, fasting and post-load insulin / C-peptide, body weight, BMI, occurrence of adverse events (total and gastro-intestinal), compliance, costs.

Differences in data extraction were resolved by consensus, referring back to the original article. If necessary, information was sought from the authors of the original studies. If necessary, we also planned to extract data from graphical figures: two reviewers (FVDL and PL) would calculate the data independently and if both outcomes were not similar, a third reviewer (EVDL) would recalculate the data. A statistician checked all extracted data for errors, after transfer to the database.

Assessment of risk of bias in included studies

The two reviewers (FVDL and PL) assessed each trial independently. Possible disagreement was resolved with consensus, or with consultation of a third reviewer (EVDL) in case of disagreement. We assessed the following quality items:

Minimisation of selection bias

- randomisation procedure: the randomisation procedure was scored 'adequate' if the resulting sequences were unpredictable (for example computer generated schemes, tables of random numbers, coin tossing).
- allocation concealment: allocation concealment was scored 'adequate' if participating patients and investigators could not foresee the assignment (for example by central randomisation remote from trial site, sequentially numbered and sealed radio-opaque envelopes).

Minimisation of performance bias

- method of blinding: blinding was scored 'adequate' if the two (or more) drugs / pills were similar in size, colour and shape or when a double-dummy method was applied. Because of the sometimes-obvious adverse effects of AGIs, true blinding is difficult. For trials that reported blinding of patients for medications, we also investigate whether blinding was checked (for example by asking patient and investigator afterwards about the medication they suspected to have been supplied with).

Minimisation of attrition bias

- handling of drop-outs: handling of drop-outs was considered 'adequate' when studies reported a complete description of all patients failing to participate until the end of the trial and if the data were analysed on intention-to-treat (ITT) basis, that means with all randomised patients included.
- quantity of dropouts: overall dropout rate less than 15% was considered 'adequate'.
- selective dropout: a difference in dropout rates between the main treatment groups less than 10% was considered 'adequate'.

Minimisation of detection bias

- method of blinding outcome-assessment: outcome assessment was considered 'adequate' if the outcome assessors were completely blind for the intervention. This item was considered less relevant for studies with laboratory data or death as main outcomes.
- method of blinding of analysis: this was considered 'adequate' if the outcome assessors (investigators, statisticians) were completely blind for the intervention up to the point that all analyses were completed. Blinding of analyses is to date not a common practice in the conduct of randomised trials. Therefore we only planned to explore possible influences of blinded analyses in a sensitivity analysis and we did not plan to use this item for the overall quality assessment.

Following these criteria, studies were broadly subdivided into the following three categories using an adapted version of the *Cochrane Handbook for Systematic Reviews of Interventions* criteria:

A - All quality criteria met (1. adequate randomisation and allocation concealment, 2. adequate blinding, 3. adequate ITT analysis or both drop-out rate less than 15% or selective drop-out less than 10%, or both 4. adequate blinding outcome-assessment): low risk of bias.

B - One or more quality criteria only partially met (1. inadequate randomisation or inadequate allocation concealment, 2. mentioning of blinding but exact method unclear, 3. inadequate/unclear ITT analysis but drop-out less than 15% or selective drop-out less than 10%, 4. mention of blinding outcome-assessment but exact method unclear): moderate risk of bias.

C - One or more quality criteria not met (1. inadequate randomisation and allocation concealment, 2. inadequate or no blinding, 3. inadequate ITT and drop-out rate equal to or greater than 15% and selective drop-out equal to or greater than 10%, 4. inadequate blinding outcome-assessment): high risk of bias.

We explored the influence of individual quality criteria in a sensitivity analysis (see under 'sensitivity analyses'). The two reviewers discussed all quality items. In cases of disagreement, a third reviewer was planned to be consulted (EVDL).

Data synthesis

The table of comparison was divided in all possible comparisons first (for example acarbose versus placebo), then sub-divided into all possible outcomes (for example death, glycated haemoglobin, adverse events) and finally, within the outcome sub-groups were made for the different dosages. Outcomes were calculated per subgroup and for all sub-groups together.

Dichotomous data were expressed as relative risks (RR). We calculated the risk difference (RD) and we converted the RD into the number needed to treat (NNT) or the number needed to harm (NNH) taking into account the time of follow-up.

Continuous data were expressed as weighted mean differences (WMD) and an overall WMD was calculated. We used the differences from baseline to endpoint as the actual measure of effect of all continuous variables. The standard deviations of these differences are essential for the data to be included in the meta-analysis. If the standard deviation (SD) of the difference were not reported, we first asked the authors to provide these data. If the SDs were not provided we estimated the SD of the difference with the following formula:

$$SD_{paired\ difference} = \sqrt{[(SD_1)^2 + (SD_2)^2 - 2 \times r \times SD_1 \times SD_2]}.$$

$SD_{paired\ difference}$ = standard deviation of the difference (pre- / post-treatment)

SD_1 = Standard deviation of the pre-treatment value, SD_2 = Standard deviation of the post-treatment value, r = correlation coefficient. We used a conservative correlation coefficient of 0.4.

Overall results were calculated based on the random effects model. Heterogeneity was statistically tested by using the Z score and the χ^2 - statistic with significance set at $P < 0.10$. Quantification of

the effect of heterogeneity was assessed by means of I^2 , ranging from 0% to 100% including its 95% confidence interval (Higgins 2002). I^2 demonstrates the percentage of total variation across studies due to heterogeneity and was used to judge the consistency of evidence. Possible sources of heterogeneity were (planned to be) assessed by subgroup, sensitivity and meta-regression analyses as described below.

The analyses were done with Review Manager (RevMan 4.2).

Subgroup analysis and investigation of heterogeneity

We planned to investigate main outcome measures by subgroup analyses in order to explore differences in effect as follows:

- glycated haemoglobin level at baseline (subdivided into groups, based on data);
- age (subdivided into groups, based on data);
- gender (subdivided into groups, based on data);
- body mass index (BMI) (subdivided into groups, based on data);
- different kinds of life-style co-interventions used (that is dietary advice, exercise, help with smoking cessation, combined interventions);
- duration of intervention (subdivided into groups, based on data);
- use of an individually titrated versus fixed dose of AGI;
- use of a step-up dose versus administering the full dose immediately.

Sensitivity analysis

We planned to perform sensitivity analyses for a number of factors by comparing the results of the meta-analysis for studies with and without certain characteristics. Data from a minimum of five studies had to be available for both groups to be considered.

The following factors were planned to be investigated:

- comparing published and unpublished studies;
- comparing studies with and without (or with unknown) quality characteristics: adequate randomisation, adequate allocation concealment, adequate method of blinding, adequate ITT analyses, adequate blinding of outcome-assessment (if applicable), adequate method of blinding of analyses. Further, comparing studies with an overall drop-out rate of more than or equal to 15% and less than 15%, differences in drop-out rates less than 10% and more than or equal to 10% between the main treatment groups. In addition, the overall score for quality based on the Cochrane criteria was used (studies with score A and B compared to studies with C);

- repeating the analyses excluding trials using the following filters: diagnostic criteria (patients with IGT or IFBG, or both), language of publication, source of funding (industry versus other or no sponsoring) or country;

- repeating the analyses using different measures of effect size (relative risk, risk difference) and different statistical models (fixed and random effects models);

- repeating the analyses excluding large studies or studies with a long duration (based on data) to establish how much they dominate the results;

- repeating the analyses excluding studies in which other risk factors for the development of type 2 diabetes or macrovascular disease were not equally distributed between treatment groups.

Meta-regression analyses

We planned to use meta-regression analyses (in SAS proc MIXED, version 8.0) to explore the influence of characteristics of study population and study design on the outcomes. We planned to examine all dependent variables for which sufficient studies are available; the minimal number of studies would need to be 10 to gain sufficient power. The independent variables were similar to the pre-defined sub-groups. The weight of each trial would be equal to the inverse sum of the within trial variance and the residual between trial variance, in order to perform a random effects analysis.

Assessment of small study bias

Small study bias was planned to be tested by using the funnel plot or other corrective analytical methods depending on the number of clinical trials included in the systematic review (Begg 1994; Egger 1997; Hedges 1992).

RESULTS

Description of studies

See: [Characteristics of included studies](#); [Characteristics of excluded studies](#); [Characteristics of ongoing studies](#).

Results of the search

Trials identified (see [Figure 1](#))

Figure 1. Study flow-diagram.

PUBMED: 224 records were retrieved and assessed on basis of title or abstract, or both (until 22 March 2006), 13 records were initially included for further reading and 12 were included in the final review.

EMBASE: 551 records were retrieved and assessed on basis of title or abstract, or both (until 21 October 2005), 20 records were initially included for further reading and 19 were included in the final review.

The Cochrane Library: 432 records were retrieved and assessed on basis of title or abstract, or both (Issue 1, 2006), 10 records were initially included for further reading. All of those records remained included in the final review.

Web of Science: 117 records were retrieved and assessed on basis of title or abstract, or both (until 7 February 2006); eight records were initially included for further reading. All of those records remained included in the final review.

LILACS: 95 records were retrieved and assessed on basis of title or abstract, or both (until 7 February 2006). None of these references were initially included.

Experts: We obtained two references by corresponding with experts or authors. One of those references was deemed interesting and could be included in the final review ([EDIT](#)).

Manufacturers: Bayer is the developer of acarbose and miglitol and Takeda the developer of voglibose. Sanofi-Synthelabo is patent holder of miglitol. Bayer send us four references, four were initially included and three were finally included in the review. Takeda and Sanofi did not reply to our letters.

Handsearching (checking references of existing reviews, browsing on the Internet, posters on congress etc.): Twenty-one references found by handsearching seemed possibly interesting based on title or abstract, or both. Nineteen references were finally included.

Databases for ongoing trials: we retrieved 43 records, four of which were initially included (last search March 22nd 2006). Thus far, we did not receive any (un)published data that gave cause to exclude those studies for the review. Two of those studies were finished by the time of retrieval (DAISI; EDIT) and two other studies were started in 2005 and will be completed in 2009 (ABC-Study) and 2013 (Tamita 2006) (see [Characteristics of ongoing studies](#) Characteristics of ongoing studies).

Interrater agreement

Interrater kappa for agreement on inclusion, calculated on basis of the first 1210 titles or abstracts, or both, read by the two reviewers (FVDL and PL) was 0.77 (95% CI 0.65 to 0.90). All differences in opinion were resolved by consensus.

Included studies

Five studies with 2360 participants, described in 36 articles, abstracts or web sites were finally included in the review. Details are given in [Characteristics of included studies](#).

Missing data

We contacted all authors for data clarification and missing data. This was successful for one study (STOP-NIDDM). The corresponding author of the DAISI study sent us the full statistical report with the restriction that we were not allowed to use the data before their manuscript was accepted for publication. The authors of the EDIT study promised us to sent more details once their manuscript was in the galley-proof stage. For the other two studies the authors did not reply to our letters and mails (Fang 2004; Wang 2000).

Publication type

Three studies were (predominantly) published as journal articles (Fang 2004; STOP-NIDDM; Wang 2000). For the STOP-NIDDM study we also considered correspondence and debate articles as a result of the main publications. The other two studies were published on a web site or as abstracts, or both (DAISI; EDIT).

Participants

Three studies included patients with IGT according to the WHO criteria of 1985 (DAISI; Fang 2004; Wang 2000). One study included participants with IGT according to the WHO criteria of 1999 in addition to a fasting blood glucose equal or greater than 5.6 mmol/L and less than 7.8 mmol/L (STOP-NIDDM) and one study included participants at increased risk for type 2 diabetes' with a fasting BG 5.5 to 7.7 mmol/L (EDIT). In the STOP-NIDDM study patients were (mainly) recruited through screening of high-risk patients and followed as outpatients in study-centres.

In the EDIT study the patients were 'self-referred' but the exact setting was unclear. Setting and recruitment for the other studies remained unclear, thus far.

Trial design

All studies had a parallel design. One study had a double-blind 2x2 factorial design (EDIT). Two studies were blinded (DAISI; STOP-NIDDM) and two studies were not blinded (Fang 2004; Wang 2000).

All studies investigated acarbose as the alpha-glucosidase inhibitor and compared it to placebo (DAISI; EDIT; STOP-NIDDM), metformin (EDIT; Fang 2004), diet and exercise (Fang 2004) or treatment, or both (Fang 2004; Wang 2000). Thus far, we found no completed studies with miglitol or voglibose.

Study duration was six years (EDIT), five years (Fang 2004), three years (DAISI; STOP-NIDDM) and one year (Wang 2000). In one study the treatment duration was followed by a three months wash-out period (placebo given for both groups, STOP-NIDDM). In all other cases treatment duration was similar to the follow-up duration.

Outcome measures

All studies reported occurrence of type 2 diabetes as a primary outcome. Data on cardiovascular morbidity and mortality was available for the STOP-NIDDM study only. For two studies additional data for glycaemic control, lipids, blood pressure and body weight were available (Fang 2004; STOP-NIDDM). The DAISI and EDIT study reported, that they investigated a number of additional outcomes (for example plasma glucose, lipids) but these data were not accessible for us thus far.

Excluded studies

Three studies were initially included but excluded after reading the full article. Two studies turned out to be not randomised (Mangiagli 2004; Yang 2001) and one study included patients with type 2 diabetes (EDIP).

Risk of bias in included studies

With respect to selection bias only one study had both an adequate randomisation and allocation concealment (STOP-NIDDM). The risk of attrition bias was low in three studies. However, no study had adequate intention-to-treat analysis. Blinding (performance bias) was adequate in one study (STOP-NIDDM) and for two studies information was lacking about precise methods of blinding (DAISI; EDIT). In one study outcomes were adequately assessed in a blinded fashion (STOP-NIDDM) (see [Table 1](#)).

The overall quality was roughly assessed on a three-point scale according to the *Cochrane Handbook for Systematic Reviews of Interventions*: one study scored A (low risk of bias) and four studies scored C (high risk of bias).

Effects of interventions

With one exception, we were unable to perform meta-analyses in this review because for none of the comparisons data were available from more than one study.

Acarbose versus placebo (see appendix 2 and data and analyses section)

Three studies compared acarbose with placebo (DAISI; EDIT; STOP-NIDDM). However, only for one study sufficient data were available to allow statistical comparison (STOP-NIDDM). For the other two studies most of the data are not yet available (DAISI; EDIT).

Mortality, incidence of type 2 diabetes and cardiovascular disease

No significant effects on total mortality and mortality due to cardiovascular causes were found (STOP-NIDDM). Data for the other two studies were missing (DAISI; EDIT).

Acarbose reduced the incidence of (conversion to) type 2 diabetes in the acarbose group: RR 0.78 (95% CI 0.68 to 0.90), Risk difference (RD) 0.09 (95% CI 0.04 to 0.14), Number Needed to Treat (NNT) = 10 (STOP-NIDDM). The NNT indicates that 10 patients have to be treated for three years with acarbose in order to prevent one case of type 2 diabetes. Also, in the EDIT-study it was reported that the use of acarbose had a preventive effect on the incidence of type 2 diabetes: RR 0.66 (P = 0.046).

In the STOP-NIDDM study a decreasing effect for acarbose on the incidence of cardiovascular disease as a combined endpoint (myocardial infarction, angina, revascularization procedures, cardiovascular death, congestive heart failure, cerebrovascular events and peripheral vascular disease) was found: RR 0.47 (95% CI 0.26 to 0.86). Also, a decreasing effect on myocardial infarctions (RR 0.08 (95% CI 0.01 to 0.64) was found. The RDs were 0.02 (95% CI 0.01 to 0.04; NNT = 50) and 0.02 (95% CI 0.01 to 0.03; NNT = 50) respectively. No significant differences in the incidence of angina pectoris, revascularization procedures, congestive heart failure, cerebrovascular events or peripheral vascular events were found. In total, 47 events took place in the whole study population and the study was not initially powered for this outcome. Thus far, we found no data on cardiovascular morbidity from the EDIT and DAISI studies.

Glycaemic control

Acarbose decreased post-load glucose by 0.61 mmol/L (95% CI 0.27 to 0.95). No significant effects on glycated haemoglobin and fasting blood glucose were observed (STOP-NIDDM).

In the EDIT study acarbose decreased fasting blood glucose by 0.1 mmol/L (P = 0.0043) and post-load blood glucose by 0.4 mmol/L (P = 0.0075).

Plasma lipids

No significant effects on lipids were found (STOP-NIDDM) or no data were available (DAISI; EDIT).

Blood pressure

In our analysis, we found no significant effects on diastolic and systolic blood pressure (Comparison 1, outcomes 41 & 42). However, in one study the authors reported a beneficial effect on the incidence of new cases of hypertension (which was not an outcome in our review) (STOP-NIDDM). In the acarbose and placebo groups 78 and 115 patients developed hypertension respectively (hazard ratio 0.66, 95% CI 0.49 to 0.89). Hypertension was defined as a blood pressure greater than 140/90 mm Hg on two visits or if the family physician added antihypertensive medication. It is remarkable that at baseline almost half of all patients were already diagnosed with hypertension (acarbose 357/682, placebo 345/686), but these participants were kept in the analysis for the development of hypertension. No data on blood pressure was available for the other studies with the comparison acarbose-placebo (DAISI; EDIT).

Fasting and post-load insulin and C-peptide

No significant effects on fasting and post-load insulin levels were found (STOP-NIDDM) or no data were available (DAISI; EDIT).

Body weight

Acarbose decreased body weight by 1.2 kg (95% CI 0.5 to 1.8) and BMI by 0.3 kg/m² (95% CI 0.1 to 0.5). For the other studies (DAISI; EDIT), no data were available.

Adverse events

Acarbose caused more gastro-intestinal side effects compared to placebo: RR 1.40 (95% CI 1.31 to 1.50) and RD 0.24 (95% CI 0.20 to 0.29; Number Needed to Harm (NNH) = 4). For the other studies, no data were available.

Quality of life

We found no data for 'quality of life', although it was stated for the EDIT study that this outcome would be measured.

Costs and compliance

Resource consumption data were not systematically collected in the STOP-NIDDM study. A cost-effectiveness study was published in which the likely consumption of healthcare resources were estimated and used for analyses.

It was reported that compliance was assessed by pill counting but we found no outcome data in the published articles. We failed to ask for those data in our correspondence with the authors.

Adjustment for high discontinuation rate in the acarbose arm of the STOP-NIDDM study (see appendix 3)

One of the main criticisms on the [STOP-NIDDM](#) study was that the discontinuation rate in the acarbose group was higher than in the placebo group (acarbose 31% versus placebo 19%). Despite the fact that discontinuing patients remained in the ITT analyses, it was suggested that those patients were not followed-up regularly every three months and thus possible occurrence of diabetes or a cardiovascular event was less likely to be discovered ([Sawicki 2004](#)).

In order to investigate the possible influence of differences in the frequency of follow-up, we re-analysed the data with the following adjustments: first we requested for the mean number of study visits for both treatment groups. Next, we divided the number of visits of the placebo group by the number of visits in the acarbose group. We used this outcome as correction factor for the number of events in the acarbose group (occurrence of cardiovascular morbidity and type 2 diabetes).

The authors of the [STOP-NIDDM](#) study reported that the mean numbers of study visit in the acarbose ($n = 682$) and in the placebo group ($n = 686$) were 13.3 (SD = 5.4) and 14.6 (SD = 4.3) respectively. The calculated correction factor was: $14.6/13.3 = 1.1$. The outcomes before and after this correction factor are listed in [Appendix 3](#). The effects sizes (Odds Ratios) of the outcomes for incidence of type 2 diabetes and occurrence of any cardiovascular disease became smaller after the correction but remained statistically significant. The (statistically significant) effects size for myocardial infarctions did not change (due to the fact that there was only one case in the acarbose group). The other outcomes remained statistically not significant after correction.

Acarbose versus metformin (see appendix 4 and data and analyses section)

One study investigated both agents in a 2x2 factorial design ([EDIT](#)). From this study no data on the comparison acarbose versus metformin is available thus far.

Another study directly compared acarbose with metformin ([Fang 2004](#)). Acarbose showed a decreasing effect on post-load blood glucose compared to metformin: 1.40 mmol/L (95% CI 0.55 to 2.25). Metformin showed a statistically significant decreasing effect on total cholesterol (0.90 mmol/L, 95% CI 0.19 to 1.61) and diastolic blood pressure (6 mmHg, 95% CI 2.81 to 9.19) compared to acarbose. No significant effects for acarbose or metformin were found for the effect on incidence of type 2 diabetes, fasting blood glucose, triglycerides, BMI or systolic blood pressure. Data

for cardiovascular events, quality of life, insulin or C-peptide levels, costs, compliance or adverse events were not found.

Acarbose versus diet and exercise (see appendix 5 and data and analyses section)

One study investigated the comparison acarbose versus diet and exercise ([Fang 2004](#)). In this study a beneficial effect of acarbose compared to diet and exercise was found on the incidence of type 2 diabetes: RR 0.40 (95% CI 0.17 to 0.96), Risk difference (RD) 0.20 (95% CI 0.02 to 0.38, NNT = 5).

Further, acarbose significantly reduced fasting blood glucose (-1.37 mmol/L, 95% CI -0.50 to -2.24) and post-load blood glucose (-2.79 mmol/L, 95% CI -1.79 to -3.79). Effects on total cholesterol, triglycerides, body weight and BMI were not statistically significant. Data for cardiovascular events, quality of life, insulin or C-peptide levels, costs, adverse events or compliance were not found.

Acarbose versus no treatment (see appendix 6 and data and analyses section)

Two studies compared acarbose with no treatment ([Fang 2004](#); [Wang 2000](#)).

Mortality, incidence of type 2 diabetes and cardiovascular disease

The combined results of the two studies indicated that acarbose reduced the incidence of type 2 diabetes: RR 0.31 (95% CI 0.14 to 0.69), Risk difference (RD) 0.17 (95% CI -0.09 to 0.43, NS). We found no data for effects on mortality or cardiovascular morbidity.

Glycaemic control

One study reported data for the effects on fasting and post-load blood glucose. Compared to patients who were given no treatment, acarbose significantly reduced fasting blood glucose (-1.39 mmol/L, 95% CI -0.54 to -2.24) and post-load blood glucose (-4.53 mmol/L, 95% CI -3.54 to -5.52) ([Fang 2004](#)).

Plasma lipids

One study reported data for the effects on total cholesterol and triglycerides. Compared to patients who were given no treatment, acarbose significantly reduced total cholesterol (-1.00 mmol/L, 95% CI -0.194 to -1.81) ([Fang 2004](#)).

Blood pressure

One study reported data for the effects of acarbose on diastolic and systolic blood pressure: no significant effects were found ([Fang 2004](#)).

Fasting and post-load insulin and C-peptide

No data were found for insulin or C-peptide levels.

Body weight

Data were available from one study: compared to patients with no treatment acarbose showed a non-significant effect on BMI (-1.1 kg/m², 95% CI -2.2 to 0, P = 0.05) (Fang 2004).

Adverse events

One study reported data on adverse effects (Wang 2000). Two patients in the acarbose group and no patients who received no treatment reported adverse effects. The difference was not statistically significant.

Quality of life

We found no data for effects on quality of life.

Costs, compliance

No data were found for these outcomes.

Sensitivity analyses, sub-group analyses, meta-regression analyses, small study bias

Due to the low number of included studies no further analyses could be performed.

Heterogeneity

Because not more than a maximum of two studies could be included per (statistical) comparison, formal testing of heterogeneity was not performed.

The studies were reasonably homogeneous with respect to a number of important items:

- all trials used acarbose as the alpha-glucosidase inhibitor (all with a dosage of 50 mg TID, except for the STOP-NIDDM study in which a dosage of 100 mg TID was given);
- all trials focused on patients with IGT (instead IFBG), except for the EDIT study which included patients 'at risk' for developing diabetes (with a fasting blood glucose 5.5 to 7.7 mmol/L);
- in all trials the number of included females and males were almost similar, ranging from 47% females (Fang 2004) to 51% females (STOP-NIDDM);
- all trials included patients with a similar age, ranging from a mean of 49.1 years (Fang 2004) to 63.5 years (Wang 2000).

The following items could cause possible heterogeneity:

- two studies were performed in an Asian population (Fang 2004; Wang 2000). The effects of alpha-glucosidase inhibitors

may be different from European or American populations (the other trials) due to differences in amount and type of carbohydrate in the regular diet;

- the mean BMI ranged from a normal BMI (Wang 2000) to overweight (Fang 2004; EDIT) or obesity (STOP-NIDDM). It was unknown for the DAISI study;

- baseline glycated haemoglobin was below 6.0% in two studies (EDIT; STOP-NIDDM), but unknown for the other studies;

- in two trials, all participants received additional advice on diet and life-style (STOP-NIDDM; Wang 2000) but for the other trials this information was missing.

DISCUSSION

Summary of main results

In this systematic review we found evidence from one large study of high quality (STOP-NIDDM) that acarbose compared to placebo reduces the incidence of type 2 diabetes and myocardial infarctions in patients with impaired glucose tolerance. These findings could not be confirmed nor refuted by two other (but highly similar) studies because most data were not available thus far (DAISI; EDIT). Two smaller studies of low quality comparing acarbose with no treatment or exercise, confirmed the capacity of acarbose to reduce the incidence of type 2 diabetes. Effects on cardiovascular morbidity could not be confirmed in other comparisons. Moreover it should be noted that the effects on cardiovascular morbidity in the STOP-NIDDM study were based on a limited number of events and the study was not initially powered for this outcome. Compared to placebo, acarbose induces more gastrointestinal side-effects (NNH = 4).

Decrease in incidence of type 2 diabetes mellitus

We found evidence from several studies that acarbose reduces the incidence of type 2 diabetes (Fang 2004; STOP-NIDDM; Wang 2000). A firm effect on the incidence of type 2 diabetes is not surprising. After all, acarbose has a clear effect on glycaemic control in patients with type 2 diabetes (Van de Laar 2005). Such a drug will have large effects on the 'incidence' of diabetes for people who are at the border of fulfilling the criteria for type 2 diabetes. So, the question is whether acarbose prevents, delays or even masks type 2 diabetes. The authors of the STOP-NIDDM study are undecided, as they sometimes speak of 'prevention' (in the title) and sometimes of 'delay' (in the summary) (Chiasson 2002). Critics of the STOP-NIDDM study suggested that acarbose masks type 2 diabetes since 15.4% of the patients on acarbose compared to 10.6% (placebo) converted to diabetes during a three months wash-out phase (Kaiser 2004).

To assess the value of acarbose with respect to the effects on the development of type 2 diabetes, it is probably more straightforward to look at the effects on glycaemic control. After all, IGT refers to an intermediate state between normal glucose homeostasis and type 2 diabetes. In the [STOP-NIDDM](#) study these effects are disappointing: no significant effect on glycated haemoglobin and fasting blood glucose, and a small effect on post-load blood glucose (-0.61 mmol/L, 95% CI -0.95 to -0.27) were found. Those effects are smaller than obtained in a Cochrane review on alpha-glucosidase inhibitors for patients with type 2 diabetes ([Van de Laar 2005](#)). This may be explained by the fact that in the before mentioned review it was found that the effects on glycaemic control were less strong with lower baseline values of glycaemia and longer study duration. Further, most trials in the Cochrane review studied post-load glucose with a full meal tolerance test, and not an oral glucose tolerance test (OGTT) as has been done in the [STOP-NIDDM](#) study. Acarbose has no direct effects on an OGTT as alpha-glucosidase inhibitors only delay the breakdown of complex polysaccharides (and not monosaccharide such as glucose). In this light, the decreasing effect of acarbose on a 2 hours OGTT is positive because it indicates a beneficial effect of insulin resistance.

Another argument in the question whether an effect of acarbose on the incidence of type 2 diabetes is relevant or important, is the desirability of a drug intervention in people at high risk for type 2 diabetes. It is well recognized that the increase in the number of patients with type 2 diabetes is in life-style factors such as a shortage of exercise and an unhealthy diet. Focussing on drugs as the solution of the problem may distract people from the issues that are truly important: eat less and exercise more.

Finally the question arises whether true (primary) prevention of type 2 diabetes with a single drug is possible at all. Type 2 diabetes is a very complex disease in which many pathophysiological mechanisms are involved (for example insulin sensitivity, blood pressure regulation). Only when one predominant mechanism would be identified, primary prevention by a drug targeting this mechanism would be feasible. Currently, it seems not likely that this will be the case for type 2 diabetes in the near future. In the mean while, drug interventions for IGT or IFBG should be regarded as secondary or tertiary prevention.

Decrease in incidence of cardiovascular disease

The observed beneficial effects on the occurrence of cardiovascular morbidity ([STOP-NIDDM](#)) are very interesting. However, these results should be interpreted with great prudence. This is underlined by the authors who sensibly stated that because effects on cardiovascular morbidity were secondary objectives and the number of events relatively small, they should be seen as hypothesis generating ([Chiasson 2004](#)).

Critics mentioned the skewed discontinuation rate as another explanation for the observed effects, other than an effect of acar-

bosc ([Sawicki 2004](#)). Because more patients in the acarbose group stopped taking their medication (mostly due to side-effects), the patients in the acarbose group were not followed-up as regular as the patients in the placebo group and could have had therefore less chance to be 'detected' in case a cardiovascular event had taken place. We re-analysed the data accounting for differences in follow-up rate and found that the odds ratios for the occurrence of any cardiovascular event became less strong, but remained statistically significant.

Another explanation could be in the existence of (unknown) confounding factors. Clues for differences in treatment groups were reported in the cost-effectiveness sub-study of the [STOP-NIDDM](#) trial ([Quilici 2005](#)). Baseline risk profiles were determined with a formula for the identification of high risk for type 2 diabetes ([Stern 2002](#)) or cardiovascular risk ([Anderson 1991](#)). Based on these risk scores, it was stated that '... more placebo patients than acarbose-treated patients were represented in the high-risk subgroups...'. So, patients in the placebo group could have had a higher a-priori risk than patients on acarbose.

We conclude that the observed effects of acarbose on cardiovascular disease may be due to a treatment effect or to (unknown) confounding factors, or both. The results from the ongoing studies are needed to confirm or refute the observed effects in the [STOP-NIDDM](#) study ([ABC-Study](#); [Tamita 2006](#)).

Effects on incidence of hypertension

We could not confirm the beneficial effects on hypertension observed in the [STOP-NIDDM](#) study, in which hypertension was studied as a clinical outcome (blood pressure greater than 140/90 mmHg on two or more occasions). Instead we studied the differences in diastolic and systolic blood pressure. These outcomes yielded no statistically significant effects of acarbose compared to placebo ([STOP-NIDDM](#)), and a detrimental effect of acarbose compared to metformin in one study of low quality and a low number of participants -6 mm Hg (95% CI 3 to 9) ([Fang 2004](#)).

Potential biases in the review process

One of the main strengths of this review is the rigourness and completeness of the search. It is remarkable that only one trial ([STOP-NIDDM](#)) was listed in the database that is mostly used by clinicians all over the world (PUBMED), and that the other studies were retrieved from less well-known databases (EMBASE or *The Cochrane Library*), in databases of ongoing trials or by hand-searching. Second, the a priori decision to include randomised trials only with a duration of at least one year ensured a 'minimum level' of quality. Third, we assessed many different outcomes in the review which enables the readers to judge by themselves what matters most for their own particular question. Finally, we think that the tables and figures and the extensive provision of all out-

come data and information related to quality and heterogeneity, makes the review transparent.

It is clear that the main limitations are the missing data, especially from the [EDIT](#) and [DAISI](#) studies. The authors have kindly promised their help once their manuscripts are accepted for publication, but it is remarkable that these important studies have not been accepted for publication to date (May 2006). This points to a possible time lag bias: a kind of reporting bias in which studies may be published rapidly or delayed depending on the nature and direction of the results. Of course we will use upcoming data from these studies, and from the studies that are still going on in future updates of our review. Another limitation is the external validity of the results. Only for one study the recruitment of the participants was clearly described. It is important to know how selection took place in order to be able to generalize the results to other clinical settings. For example, were the participants volunteers recruited with an newspaper advertisement (and thus highly motivated), or were they recruited from the files of general practitioners (and maybe less motivated). Further, we only found studies with acarbose as the AGI. The question whether the results may be extrapolated to miglitol or voglibose depends on the existence of a possible group effect for AGIs. The answer to this question is not known, although in the Cochrane review on AGIs for type 2 diabetes comparable results for acarbose and miglitol were obtained for most outcomes ([Van de Laar 2005](#)).

Agreements and disagreements with other studies or reviews

As far as we are aware of, no systematic review has been done with an exclusive focus on alpha-glucosidase inhibitors for people with IGT or IFBG. Nevertheless, alpha-glucosidase inhibitors have been studied as part of a recent systematic review on all kind of drug therapy to delay or prevent type 2 diabetes ([Padwal 2005](#)). In that review two studies on acarbose were included: the [STOP-NIDDM](#) study, and a non-randomised study ([Yang 2001](#)) (excluded for the current review). It was concluded that acarbose reduced the incidence of type 2 diabetes compared with placebo but that it could not definitively be recommended for diabetes prevention. Similar conclusions were drawn for metformin, troglitazone and orlistat (a weight reducing agent). Further, inconclusive results for a decrease in the incidence of type 2 diabetes were reported for cholesterol lowering agents (fibrates and statins), an-

ti-hypertensive agents and oestrogens. A systematic review on the efficacy of lifestyle education concluded that lifestyle education was clearly effective for reducing two-hour plasma glucose (0.84 mmol/L, 95% CI 0.39 to 1.29) and the incidence of type 2 diabetes over one year (RR 0.55, 95% CI 0.44 to 0.69), and should thus be recommended for patients with patients at high risk for type 2 diabetes ([Yamaoka 2005](#)).

AUTHORS' CONCLUSIONS

Implications for practice

In patients with impaired glucose tolerance the use of acarbose reduces the incidence of type 2 diabetes, but the effects on glycaemic control are limited. Acarbose has a possible effect on cardiovascular morbidity, which has to be confirmed in other studies. Life-style interventions remain the cornerstone of treatment for patients at risk for type 2 diabetes. If physicians and patients feel that an active treatment for impaired glucose tolerance is needed, they should consider this evidence together with evidence for other interventions, especially life-style interventions.

Implications for research

First, the disclosure of the finished - but unpublished - studies is needed in order to confirm or refute the possible effects on cardiovascular morbidity. If the evidence remains inconclusive after these data have been incorporated in the systematic review, the results from two ongoing long-term intervention studies on the effects of alpha-glucosidase inhibitors for patients with IGT or IFBG may be awaited. Otherwise, new long-term studies with a similar focus could be initiated.

ACKNOWLEDGEMENTS

We would like to thank the following people: all authors, investigators and manufacturers who were willing to answer our questions and who provided us with additional data.

Bas Aarts for the translation of the articles from Chinese language, and Leon Bax for the translation of abstracts in the Japanese language.

REFERENCES

References to studies included in this review

DAISI {published data only}

Nijpels G. Dutch Acarbose Intervention Trial (DAISI). <http://www.controlled-trials.com/iscrt/trial/0/33274262.html> accessed 15th march 2006 2005.
Nijpels G, Ruige J. Dutch Acarbose Intervention Study in IGT (DAISI). http://www.emgo.nl/research_prog/diabetes/researchprojects_01.asp (accessed sept 14th 2004) 2004.

EDIT {published data only}

Anonymous. Early Diabetes Intervention Trial (protocol). <http://www.dtu.ox.ac.uk/> accessed 15th march 2006.
Cirroën HA, Tunbridge FKE, Holman RR. Possible prevention of type 2 diabetes with acarbose or metformin over three years. *Diabetologia* 2000;**43**(Suppl. 1):A73.
Holman RR. Early Diabetes Intervention Trial (EDIT Study). <http://www.controlled-trials.com/iscrt/trial/0/96631607.html> accessed 13 march 2006 2002.
Holman RR, Blackwell L, Manley SE, Tucker L, Frighi V, Stratton IM. Results from the early diabetes intervention trial. *Diabetes* 2003;**52**(Suppl. 1):A16.
Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V. Six-years results from the Early Diabetes Intervention Trial. *Diabetic Medicine* 2003;**20**(Suppl. 2):15.
Holman RR, North BV, Tunbridge FKE. Early diabetes intervention trial. *Diabetologia* 1997; Vol. 40, issue Suppl. 1:A17.
* Holman RR, North BV, Tunbridge FKE. Early Diabetes Intervention Trial. *Diabetes* 1997;**46**(Suppl 1):157A.
Holman RR, North BV, Tunbridge FKE. Possible prevention of type 2 diabetes with acarbose or metformin. *Diabetes YR* 2000;**49**(Suppl. 1):450–P.

Fang 2004 {published data only}

* Fang YS, Li TY, Chen SY. Effect of medicine and non-medicine intervention on the outcomes of patients with impaired glucose tolerance: 5-year follow-up [Chinese]. *Zhongguo Linchuang Kangfu (Chinese Journal for Clinical Rehabilitation)* 2004;**8**(30):6562–3.

STOP-NIDDM {published and unpublished data}

Anonymous. STOP-NIDDM (Flash player presentation). www.stop-niddm.com accessed 8 february 2006 www.stop-niddm.com accessed 8th february 2006 2006.
Anonymous. The “STOP NIDDM” program—can diabetes in the aged be prevented? An international long-term study revisited; does Acarbose delay or prevent the manifestations of type II diabetes [STOP NIDDM Programm – Kann man den Altersdiabetes verhindern? Eine internationale Langzeit-Studie untersucht, ob Acarbose die Manifestation des Typ II–Diabetes verzögert oder verhindert]. *Deutsche Medizinische Wochenschrift* 1997;**122**(38 Suppl):1–4.
Anonymous. The STOP-NIDDM Trial Study TO Prevent non insulin dependent diabetes mellitus (powerpoint

presentation). <http://www.stop-niddm.com/study/slides/htm> accessed 1st august 2003.

Bridges CM. Acarbose for patients with hypertension and impaired glucose tolerance. *JAMA* 2003;**290**(23):3066–7.
Chiasson JL. The potential use of acarbose in the prevention of type 2 diabetes and cardiovascular disease. *European Heart Journal Supplements* 2000;**2**(Supplement D):D35.
Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. *Diabetes Care* 1998;**21**(10):1720–5.

* Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* 2002;**359**(9323):2072–7.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. *Diabetologia* 2004;**47**(6):969–75.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA* 2003;**290**(4):486–96.

Chiasson JL, Josse RG, Hanefeld M, Karasik A, Laakso M. Acarbose can prevent type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: The STOP-NIDDM Trial. *Diabetologia* 2002;**45**(Suppl 2):A104.

Delorme S, Chiasson JL. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. *Current Opinion in Pharmacology* 2005;**5**(2):184–9.

Gonzalez-Clemente JM, Ortega-Martinez d, V, Gimenez-Palop O, Mauricio D. Acarbose for patients with hypertension and impaired glucose tolerance. *JAMA* 2003;**290**(23):3067–9.

Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. *Stroke* 2004;**35**(5):1073–8.
Kaiser T, Sawicki PT. Acarbose for patients with hypertension and impaired glucose tolerance. *JAMA* 2003;**290**(23):3066–9.

Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. *Diabetologia* 2004;**47**(3):

575–80.

Muhlhauser I. Acarbose for type 2 diabetes prevention. *Lancet* 2002;**360**(9344):1517.

Quilici S, Chancellor J, MacLaine G, McGuire A, Andersson D, Chiasson JL. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden. *International Journal of Clinical Practice* 2005;**59**(10):1143–52.

Rosenthal JH. Acarbose for patients with hypertension and impaired glucose tolerance. *JAMA* 2003;**290**(23):3066.

Sabes R. Cost-effectiveness analysis of acarbose in the treatment of patients with impaired glucose tolerance. *Gaceta sanitaria / SESPAS* 2004;**18**(6):431–9.

Sawicki PT, Kaiser T. Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. *Diabetologia* 2004;**47**(6):976–7.

Scheen AJ. Acarbose for type 2 diabetes prevention. *Lancet* 2002;**360**(9344):1516.

Temelkova-Kurktschiev TS, Koehler C. Lower progression of carotid intima media thickness under acarbose: the STOP-NIDDM study. *Diabetologia* 2003;**46**(Suppl 2):A122–3.

Windler E. Acarbose for prevention of diabetes mellitus. STOP-NIDDM [Acarbose zur Diabetes–mellitus–Pravention]. *Der Internist* 2003;**44**(4):491–3.

Zeymer U. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. *International Journal of Cardiology* 2006;**107**(1):11–20.

Zeymer U. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. *International Journal of Cardiology* 2006;**107**(1):11–20.

Zeymer U, Schwarzmaier-D'assie A, Petzinna D, Chiasson JL. Acarbose reduces silent myocardial infarctions in patients with impaired glucose tolerance. Results of the randomized STOP-NIDDM ECG substudy. *Diabetologia* 2004;**47**(Suppl 1):A47.

Wang 2000 {published data only}

* Wang H, Xu WH, Wang GY. An evaluation on efficacy of acarbose interfering treatment on IGT [Chinese]. *Shanxi Clinical Medicine Journal* 2000;**9**(2):116–7.

References to studies excluded from this review

EDIP {published data only}

Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD. HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). *Diabetes Care* 2001;**24**(3):465–71.
Shankar RR, Shankar SS, Brizendine E, Shen G, McGill J, Baron AD, Kirkman MS. Acarbose in 'Early' Diabetes - Data from the Early Diabetes Intervention Program (EDIP). *Diabetes* 2005;**54**(Suppl 1):A132.

Mangiagli 2004 {published data only}

Mangiagli A, Campisi S, De Sanctis V, Nicoletti MC, Cardinale G, Galati MC, Raiola G, Rigano P, Saviano A. Effects of acarbose in patients with beta-thalassaemia major and abnormal glucose homeostasis. *Pediatric Endocrinology Reviews* 2004;**2**(Suppl 2):276–8.

Yang 2001 {published data only}

* Yang W, Lin L, Qi J, Yu Z, Pei H, He G, Yang Z, Wang F, Li G, Pan X. The preventive effect of Acarbose and Metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study [translated from Chinese, available from Bayer website www.stop-niddm.com, accessed september 13th 2004]. *Chinese Journal of Endocrinology and Metabolism* 2001;**17**(3):131–6.

References to ongoing studies

ABC-Study {published data only}

Kim J. Alpha-Glucosidase-Inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT (ABC Study). <http://clinicaltrials.gov/show/NCT00212017> accessed 15th march 2006 2006.

Tamita 2006 {published data only}

Tamita K. Acarbose for Secondary Prevention of Cardiovascular Events in Patients With Coronary Stenting and Abnormal Glucose Tolerance. <http://clinicaltrials.gov/show/NCT00221156> accessed 15th march 2006.

Additional references

ADA 1997

American Diabetic Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997;**20**:1183–97.

ADA 1999

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1999;**22** Suppl 1:S5–19.

ADA 2003

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up Report on the Diagnosis of Diabetes Mellitus. *Diabetes Care* 2003;**26**(11):3160–7.

Anderson 1991

Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. *American Heart Journal* 1991;**121**(1 Pt 2):293–8.

Begg 1994

Begg CB, Mazumbar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;**50**:1088–101.

Buchanan 2002

Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic β -cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. *Diabetes* 2002;**51**(9):2796–803.

Chiasson 2002

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* 2002;**359**(9323):2072–7.

Chiasson 2003

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA* 2003;**290**(4):486–94.

Chiasson 2004

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. *Diabetologia* 2004;**47**(6):969–75.

Cohen 1960

Cohen J. A coefficient of agreement for nominal scales. *Educational and Psychological Measurement* 1960;**20**:37–46.

Egger 1997

Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629–34.

Hedges 1992

Hedges LV. Modeling publication selection effects in meta-analysis. *Statistical Science* 1992;**7**:246–55.

Higgins 2002

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;**21**(11):1539–58.

Kaiser 2004

Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. *Diabetologia* 2004;**47**(3):575–80.

Knowler 2002

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *New England Journal of Medicine* 2002;**346**(6):393–403.

NDDG 1979

National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 1979;**28**:1039–57.

Padwal 2005

Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. *Diabetes Care* 2005;**28**(3):736–44.

Pan 1997

Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* 1997;**20**(4):537–44.

Quilici 2005

Quilici S, Chancellor J, MacLaine G, McGuire A, Andersson D, Chiasson JL. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden. *International Journal of Clinical Practice* 2005;**59**(10):1143–52.

Robinson 2002

Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. *International Journal of Epidemiology* 2002;**31**(1):150–3.

Sawicki 2004

Sawicki PT, Kaiser T. Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. *Diabetologia* 2004;**47**(6):976–7.

Stern 2002

Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?. *Annals of Internal Medicine* 2002;**136**(8):575–81.

Tuomilehto 2001

Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *New England Journal of Medicine* 2001;**344**(18):1343–50.

Unwin 2002

Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. *Diabetic Medicine* 2002;**19**(9):708–23.

Van de Laar 2005

Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, Rutten GEHM, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews* 2005, Issue 2. [Art. No.: CD003639. DOI: 10.1002/14651858.CD003639.pub2]

WHO 1980

World Health Organisation. WHO Technical Report Series 646. Second report. WHO Expert Committee on Diabetes Mellitus 1980.

WHO 1985

World Health Organisation. Technical Report Series No. 727. Report of a WHO Study Group. WHO Expert Committee on Diabetes Mellitus 1985.

WHO 1998

Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. *Diabetic Medicine* 1998;**15**:539–53.

WHO 1999

World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications.. *Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus*. Geneva: World Health Organization, 1999:1–59.

Yamaoka 2005

Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. *Diabetes Care* 2005;**28**(11):2780–6.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

DAISI

Methods	DESIGN: parallel study RANDOMISATION PROCEDURE: unclear BLINDING: double-blind DURATION: 3 years (treatment and follow-up)	
Participants	COUNTRY: Netherlands SETTING: unclear RECRUITMENT: unclear DIAGNOSTIC CRITERIA: 2-hour post-load BG > 8.6 mmol/L and < 11.1 mmol/L after 2 OGTTs (WHO 1985) NUMBER: AGI: included 61, completed 27, ITT 60, PP 32; CONTROL included 60, completed 33, ITT 58, PP 39 SEX: 'sex ratio nearly 1:1' AGE (YEARS (MEDIAN)): AGI 61; CONTROL 56 BMI (KG/M2 (MEAN)): ND GLYCATED HAEMOGLOBIN: ND	
Interventions	Dietary advice: unclear AGI: acarbose, week 1 50 mg OD; week 2 50 mg BID; week 3 - endpoint 30 mg TID CONTROL: placebo, dosing schedule not described	
Outcomes	1. Mortality: unclear 2. Complications related to hyperglycaemia: incidence of type 2 diabetes and 'conversion to' normal glucose tolerance 3. Quality of Life: unclear 4. Glycaemic control: fasting venous glucose 5. Lipids: Total- & HDL-cholesterol, triglycerides 6. Insulin levels: B-cell function and insulin sensitivity 7. Weight: unclear 8. Blood pressure: unclear 9. Adverse effects: unclear 10. Costs: unclear	
Notes	Sponsor: Bayer, manufacturer of acarbose Author contacted: yes, we received the statistical report, but we were not allowed to use these data before the manuscript of the original study was accepted for publication. Study retrieved: databases of ongoing studies, handsearching	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

EDIT

Methods	DESIGN: parallel study, 2x2 factorial design, patients randomised for both acarbose and metformin versus placebo RANDOMISATION PROCEDURE: unclear BLINDING: double-blind DURATION: 6 years (treatment and follow-up)	
Participants	COUNTRY: United Kingdom SETTING: unclear RECRUITMENT: unclear, 'self-referred' DIAGNOSTIC CRITERIA: Patients 'at risk' for developing diabetes, Fasting BG 5.5-7.7 mmol/L NUMBER: recruited 671, randomised 631 SEX: 51% Female, 49% Male AGE (YEARS (MEAN (SD))): randomised patients 52,1 (10,0) BMI (KG/M2 (MEAN (SD)))): randomised patients 28,6 (4,5) GLYCATED HAEMOGLOBIN (% (MEAN (SD)))): all randomised patients 5.9 (0.5)	
Interventions	Dietary advice: unclear 2X2 Factorial design, four possible treatments: AGI: acarbose 50 mg TID + placebo TID CONTROL1: placebo TID + placebo TID CONTROL2: metformin 500 mg TID + placebo TID CONTROL3: metformin 500 mg TID + acarbose 50 mg TID	
Outcomes	1. Mortality: unclear 2. Complications related to hyperglycemia: progression to type 2 diabetes 3. Quality of Life: yes 4. Glycaemic control: fasting BG 5. Lipids: 'lipid profiles' 6. Insulin levels: beta-cell function and insulin sensitivity 7. Weight: body weight 8. Blood pressure: unclear 9. Adverese effects: unclear 10. Costs: unclear	
Notes	Because we planned to investigate AGI monotherapy, we will not consider the outcomes for the combination group (acarbose + metformin) Sponsor: funded by an educational grant from Bayer and Merck-Lipha Author contacted: study currently submitted for publication, the manuscript will be made accessible when the galley proof is available. Study retrieved: databases of ongoing studies, handsearching, experts	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

Fang 2004

Methods	DESIGN: parallel RANDOMISATION PROCEDURE: adequate BLINDING: no mention of blinding or use of placebo DURATION: 5 years (treatment and follow-up)
Participants	COUNTRY: China SETTING: unclear RECRUITMENT: selected volunteers, details missing DIAGNOSTIC CRITERIA: IGT according to WHO 1985 NUMBER: 549 volunteers screened; 178 cases of IGT included: AGI 50, CONTROL1 40, CONTROL2 48, CONTROL3 40; analysed AGI 45, CONTROL1 35, CONTROL2 44, CONTROL3 36 SEX (F/M): AGI 22/28, CONTROL1 18/22, CONTROL2 22/26, CONTROL3 22/18 AGE (YEARS (MEAN (SD))): analysed patients: AGI 50 (7), CONTROL1 47 (14), CONTROL2 50 (7), CONTROL3 49 (6) BMI (KG/M2 (MEAN (SD))) : analysed patients: AGI 24.9 (2.1), CONTROL1 24.8 (2.5), CONTROL2 25.2 (2.8), CONTROL3 25.3 (1.9) GLYCATED HAEMOGLOBIN: ND
Interventions	Dietary advice: unclear AGI: acarbose 25-50 mg TID CONTROL1: no treatment (common diabetes prevention education) CONTROL2: flumamine (= metformin) 125-250 mg TID CONTROL3: Diet and exercise: Education and dietary advice and exercise based on personal situation
Outcomes	1. Mortality: ND 2. Complications related to hyperglycaemia: incidence of type 2 diabetes 3. Quality of Life: ND 4. Glycaemic control: fasting and 2-hours post-prandial blood glucose 5. Lipids: total cholesterol & triglycerides 6. Insulin levels: ND 7. Weight: BMI 8. Blood pressure: systolic & diastolic blood pressure 9. Adverse effects: ND 10. Costs: ND
Notes	Sponsor: unclear Author contacted: yes, no reply Study retrieved: EMBASE

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

STOP-NIDDM

Methods	DESIGN: parallel study RANDOMISATION PROCEDURE: adequate BLINDING: double-blind DURATION: mean 3.3 years (SD 1.5) treatment period, followed by a three months wash out period	
Participants	COUNTRIES: Canada, Germany, Austria, Norway, Denmark, Sweden, Finland, Israel, Spain SETTING: Outpatients RECRUITMENT: through screening of high-risk populations, and in particular from first degree relatives of patients with type 2 diabetes DIAGNOSTIC CRITERIA: IGT (WHO 1999): 2 hour BG >=7.8 and < 11.1 mmol/L and fasting BG >=5.6 and <7.8 mmol/L NUMBER: randomised 1429, analysed 1368 (AGI 682, CONTROL 686); medication discontinuation, AGI 230/682, CONTROL 130/686 SEX (F/M): analysed group AGI 353/329, CONTROL 342/344 AGE (YEARS (MEAN (SD))): analysed patients: AGI 54.3 (7.9), CONTROL 54.6 (7.9) BMI (KG/M2 (MEAN (SD))) : analysed patients: AGI 31.0 (4.3), CONTROL 30.9 (4.2) GLYCATED HAEMOGLOBIN (% (MEAN (SD))) : analysed patients: AGI 5.24 (0.74), CONTROL 5.24 (0.78)	
Interventions	Dietary advice: all patients were instructed to go on a weight-reduction or weight-maintenance diet and were encouraged to exercise regularly; these instructions were reinforced at each visit AGI: acarbose, started with 50 mg (once daily) and uptitrated to 100 mg TID or maximum tolerated dose. Mean daily dose 194 mg (SD 87) CONTROL: placebo, dosage adjusted similar to acarbose, 'mean daily dose' was 238 mg (SD missing)	
Outcomes	1. Mortality: yes 2. Complications related to hyperglycaemia: incidence of diabetes & cardiovascular events 3. Quality of Life: ND 4. Glycaemic control: glycated haemoglobin, fasting & post-load blood glucose 5. Lipids: Total-, HDL & LDL-cholesterol, triglycerides 6. Insulin levels: fasting & post-load insulin 7. Weight: body weight, BMI 8. Blood pressure: Diastolic & Systolic blood pressure, occurrence of hypertension 9. Adverse effects: yes 10. Costs: ND	
Notes	Sponsor: Bayer, manufacturer of acarbose Author contacted: additional data sent by author Study retrieved: PUBMED, CENTRAL, EMBASE, WOS, Handsearch, manufacturer	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Yes	A - Adequate

Wang 2000

Methods	DESIGN: parallel RANDOMISATION PROCEDURE: unclear BLINDING: not blinded DURATION: 1 year (treatment and follow-up)	
Participants	COUNTRY: China SETTING: unclear RECRUITMENT: unclear DIAGNOSTIC CRITERIA: IGT according to WHO 1985 NUMBER: randomised AGI 31, CONTROL 30; analysed AGI 30, CONTROL 30 SEX (F/M): AGI 15/16, CONTROL 14/16 AGE (YEARS (MEAN (SD))): AGI 64.0 (8.7), CONTROL 63.0 (7.0) BMI (KG/M2 (MEAN (SD)))): AGI 22.7 (3.4), CONTROL 21.0 (3.0) GLYCATED HEMOGLOBIN: ND	
Interventions	Dietary advice: 5 hours training about diet in treatment and prevention of type 2 diabetes AGI: acarbose 50 mg TID CONTROL: no treatment	
Outcomes	1. Mortality: ND 2. Complications related to hyperglycemia: incidence of type 2 diabetes 3. Quality of Life: ND 4. Glycaemic control: ND 5. Lipids: ND 6. Insulin levels: ND 7. Weight: ND 8. Blood pressure: ND 9. Adverese effects: yes 10. Costs: ND	
Notes	Sponsor: unclear Author contacted: yes, no reply Study retrieved: CENTRAL	
Risk of bias		
Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

BG = Blood Glucose; BID = Bis In Die (twice daily); BMI = Body Mass Index; IGT = Impaired Glucose Tolerance; ITT = Intention To Treat Population; ND = No Data; OD = once daily; OGTT = Oral Glucose Tolerance Test; PP = Per Protocol Population; TID = Ter In Die (three times a day)

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
EDIP	All enrolled subjects have type 2 diabetes (as defined by a 2-hours post load plasma glucose $\geq$ 11.1 mmol/L)
Mangiagli 2004	Study was not randomised
Yang 2001	No mention of randomisation in the translated manuscript. Attempts to contact the authors failed (e-mails were rejected)

Characteristics of ongoing studies *[ordered by study ID]***ABC-Study**

Trial name or title	Alpha-Glucosidase-Inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT (ABC Study)
Methods	
Participants	Patients with IGT and old myocardial infarction.
Interventions	acarbose versus standard diet and exercise treatment
Outcomes	Primary outcomes: 1 cardiovascular mortality; 2 hospitalisation due to cardiovascular events; Secondary outcomes: 1 all cause mortality; 2 hospitalisation due to coronary artery disease; 3 progression of IGT to diabetes; 4 development or deterioration of either hypertension or hyperlipidaemia; 5 deterioration of renal function; 6 hospitalisation due to cerebrovascular disease; 7 hospitalisation due to heart failure
Starting date	April 2005; last follow-up April 2009
Contact information	Masafumi Kitakaze MD, PhD Tel: 81-6-6833-5012 ext.: 2225 kitakaze@zf6.so-net.ne.jp
Notes	

Tamita 2006

Trial name or title	Acarbose and Secondary Prevention After Coronary Stenting
Methods	
Participants	patients with abnormal glucose tolerance and coronary artery disease
Interventions	acarbose versus standard lifestyle modification

Tamita 2006 (Continued)

Outcomes	Primary outcome: cardiovascular event free survival time. Secondary outcomes: 1 conversion of abnormal glucose tolerance to type 2 diabetes; 2 all cause of death; 3 occurrence of every cardiovascular event; 4 occurrence of in-stent restenosis; 5 regression of intimal plus medial complex of the carotid artery; 6 change in fasting, 2-hour blood glucose and insulin level; 7 change in homeostasis model assessment of insulin resistance; 8 change in HbA1c; 9 change in lipid profile
Starting date	May 2005; last follow-up April 2013
Contact information	Koichi Tamita ,MD Tel: +81-78-304-4321 k-tamita@kcgh.gr.jp
Notes	

DATA AND ANALYSES

Comparison 1. Acarbose versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of type 2 diabetes mellitus	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
1.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
2 Occurrence of death (total)	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
2.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
3 Occurrence of cardiovascular death	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
3.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
4 Occurrence of cardiovascular disease (any)	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
4.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
5 Occurrence of myocardial infarctions	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
5.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
6 Occurrence of angina pectoris	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
6.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
7 Occurrence of revascularisation procedures	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
7.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
8 Occurrence of congestive heart failure	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
8.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
9 Occurrence of cerebrovascular events	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
9.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
10 Occurrence of peripheral vascular events	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
10.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
11 Change in glycated haemoglobin (%)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
11.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
12 Change in fasting blood glucose (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
12.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
13 Change in post-load blood glucose (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
13.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
14 Change in total cholesterol (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
14.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
15 Change in HDL-cholesterol (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

15.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
16 Change in LDL-cholesterol (mmol/l)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
16.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
17 Change in triglycerides (mmol/l)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
17.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
18 Change in fasting insulin levels (pmol/l)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
18.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
19 Change in post-load insulin levels (pmol/l)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
19.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
20 Change in body weight (Kg)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
20.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
21 Change in body mass index (Kg/m2)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
21.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
22 Change in diastolic blood pressure (mmHg)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
22.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
23 Change in systolic blood pressure (mmHg)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
23.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
24 Occurrence of side effects (total)	1	Odds Ratio (M-H, Random, 95% CI)	Totals not selected
24.1 Acarbose 100 mg TID	1	Odds Ratio (M-H, Random, 95% CI)	Not estimable
25 Occurrence of gastro-intestinal side-effects	1	Odds Ratio (M-H, Random, 95% CI)	Totals not selected
25.1 Acarbose 100 mg TID	1	Odds Ratio (M-H, Random, 95% CI)	Not estimable

Comparison 2. Acarbose versus metformin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of type 2 diabetes mellitus	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
1.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
2 Change in fasting blood glucose (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
2.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
3 Change in post-load blood glucose (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
4 Change in total cholesterol (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
4.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
5 Change in triglycerides (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected

5.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
6 Change in body mass index (Kg/m2)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
6.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
7 Change in diastolic blood pressure (mmHg)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
7.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable
8 Change in systolic blood pressure (mmHg)	1	Mean Difference (IV, Random, 95% CI)	Totals not selected
8.1 Acarbose 100 mg TID	1	Mean Difference (IV, Random, 95% CI)	Not estimable

Comparison 3. Acarbose versus diet and exercise

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of type 2 diabetes mellitus	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
1.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
2 Change in fasting blood glucose (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
2.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
3 Change in post-load blood glucose (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
4 Change in total cholesterol (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
4.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
5 Change in triglycerides (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
5.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
6 Change in body mass index (Kg/m2)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
7 Change in diastolic blood pressure (mmHg)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
7.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
8 Change in systolic blood pressure (mmHg)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
8.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable

Comparison 4. Acarbose versus no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of type 2 diabetes mellitus	2	140	Odds Ratio (M-H, Random, 95% CI)	0.22 [0.08, 0.59]
1.1 Acarbose 100 mg TID	2	140	Odds Ratio (M-H, Random, 95% CI)	0.22 [0.08, 0.59]
2 Change in fasting blood glucose (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
2.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
3 Change in post-load blood glucose (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
4 Change in total cholesterol (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
4.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
5 Change in triglycerides (mmol/l)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
5.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
6 Change in body mass index (Kg/m2)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
7 Change in diastolic blood pressure (mmHg)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
7.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
8 Change in systolic blood pressure (mmHg)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
8.1 Acarbose 100 mg TID	1		Mean Difference (IV, Random, 95% CI)	Not estimable
9 Occurrence of side effects (total)	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
9.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable
10 Occurrence of gastro-intestinal side-effects	1		Odds Ratio (M-H, Random, 95% CI)	Totals not selected
10.1 Acarbose 100 mg TID	1		Odds Ratio (M-H, Random, 95% CI)	Not estimable

Analysis 1.1. Comparison 1 Acarbose versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 1 Incidence of type 2 diabetes mellitus

Analysis 1.2. Comparison 1 Acarbose versus placebo, Outcome 2 Occurrence of death (total).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 2 Occurrence of death (total)

Analysis 1.3. Comparison 1 Acarbose versus placebo, Outcome 3 Occurrence of cardiovascular death.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 3 Occurrence of cardiovascular death

Analysis 1.4. Comparison 1 Acarbose versus placebo, Outcome 4 Occurrence of cardiovascular disease (any).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 4 Occurrence of cardiovascular disease (any)

Analysis 1.5. Comparison 1 Acarbose versus placebo, Outcome 5 Occurrence of myocardial infarctions.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 5 Occurrence of myocardial infarctions

Analysis 1.6. Comparison 1 Acarbose versus placebo, Outcome 6 Occurrence of angina pectoris.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 6 Occurrence of angina pectoris

Analysis 1.7. Comparison 1 Acarbose versus placebo, Outcome 7 Occurrence of revascularisation procedures.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 7 Occurrence of revascularisation procedures

Analysis 1.8. Comparison 1 Acarbose versus placebo, Outcome 8 Occurrence of congestive heart failure.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 8 Occurrence of congestive heart failure

Analysis 1.9. Comparison 1 Acarbose versus placebo, Outcome 9 Occurrence of cerebrovascular events.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 9 Occurrence of cerebrovascular events

Analysis 1.10. Comparison 1 Acarbose versus placebo, Outcome 10 Occurrence of peripheral vascular events.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 10 Occurrence of peripheral vascular events

Analysis 1.11. Comparison 1 Acarbose versus placebo, Outcome 11 Change in glycated haemoglobin (%).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 11 Change in glycated haemoglobin (%)

Analysis 1.12. Comparison 1 Acarbose versus placebo, Outcome 12 Change in fasting blood glucose (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 12 Change in fasting blood glucose (mmol/l)

Analysis 1.13. Comparison 1 Acarbose versus placebo, Outcome 13 Change in post-load blood glucose (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 13 Change in post-load blood glucose (mmol/l)

Analysis 1.14. Comparison 1 Acarbose versus placebo, Outcome 14 Change in total cholesterol (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 14 Change in total cholesterol (mmol/l)

Analysis 1.15. Comparison 1 Acarbose versus placebo, Outcome 15 Change in HDL-cholesterol (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 15 Change in HDL-cholesterol (mmol/l)

Analysis 1.16. Comparison 1 Acarbose versus placebo, Outcome 16 Change in LDL-cholesterol (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 16 Change in LDL-cholesterol (mmol/l)

Analysis 1.17. Comparison 1 Acarbose versus placebo, Outcome 17 Change in triglycerides (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 17 Change in triglycerides (mmol/l)

Analysis 1.18. Comparison 1 Acarbose versus placebo, Outcome 18 Change in fasting insulin levels (pmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 18 Change in fasting insulin levels (pmol/l)

Analysis 1.19. Comparison 1 Acarbose versus placebo, Outcome 19 Change in post-load insulin levels (pmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 19 Change in post-load insulin levels (pmol/l)

Analysis 1.20. Comparison 1 Acarbose versus placebo, Outcome 20 Change in body weight (Kg).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 20 Change in body weight (Kg)

Analysis 1.21. Comparison 1 Acarbose versus placebo, Outcome 21 Change in body mass index (Kg/m2).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 21 Change in body mass index (Kg/m2)

Analysis 1.22. Comparison 1 Acarbose versus placebo, Outcome 22 Change in diastolic blood pressure (mmHg).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 22 Change in diastolic blood pressure (mmHg)

Analysis 1.23. Comparison 1 Acarbose versus placebo, Outcome 23 Change in systolic blood pressure (mmHg).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 23 Change in systolic blood pressure (mmHg)

Analysis 1.24. Comparison 1 Acarbose versus placebo, Outcome 24 Occurrence of side effects (total).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 24 Occurrence of side effects (total)

Analysis 1.25. Comparison 1 Acarbose versus placebo, Outcome 25 Occurrence of gastro-intestinal side-effects.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 1 Acarbose versus placebo

Outcome: 25 Occurrence of gastro-intestinal side-effects

Analysis 2.1. Comparison 2 Acarbose versus metformin, Outcome 1 Incidence of type 2 diabetes mellitus.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 2 Acarbose versus metformin

Outcome: 1 Incidence of type 2 diabetes mellitus

Analysis 2.2. Comparison 2 Acarbose versus metformin, Outcome 2 Change in fasting blood glucose (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 2 Acarbose versus metformin

Outcome: 2 Change in fasting blood glucose (mmol/l)

Analysis 2.3. Comparison 2 Acarbose versus metformin, Outcome 3 Change in post-load blood glucose (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 2 Acarbose versus metformin

Outcome: 3 Change in post-load blood glucose (mmol/l)

Analysis 2.4. Comparison 2 Acarbose versus metformin, Outcome 4 Change in total cholesterol (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 2 Acarbose versus metformin

Outcome: 4 Change in total cholesterol (mmol/l)

Analysis 2.5. Comparison 2 Acarbose versus metformin, Outcome 5 Change in triglycerides (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 2 Acarbose versus metformin

Outcome: 5 Change in triglycerides (mmol/l)

Analysis 2.6. Comparison 2 Acarbose versus metformin, Outcome 6 Change in body mass index (Kg/m2).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 2 Acarbose versus metformin

Outcome: 6 Change in body mass index (Kg/m2)

Analysis 2.7. Comparison 2 Acarbose versus metformin, Outcome 7 Change in diastolic blood pressure (mmHg).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 2 Acarbose versus metformin

Outcome: 7 Change in diastolic blood pressure (mmHg)

Analysis 2.8. Comparison 2 Acarbose versus metformin, Outcome 8 Change in systolic blood pressure (mmHg).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 2 Acarbose versus metformin

Outcome: 8 Change in systolic blood pressure (mmHg)

Analysis 3.1. Comparison 3 Acarbose versus diet and exercise, Outcome 1 Incidence of type 2 diabetes mellitus.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 3 Acarbose versus diet and exercise

Outcome: 1 Incidence of type 2 diabetes mellitus

Analysis 3.2. Comparison 3 Acarbose versus diet and exercise, Outcome 2 Change in fasting blood glucose (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 3 Acarbose versus diet and exercise

Outcome: 2 Change in fasting blood glucose (mmol/l)

Analysis 3.3. Comparison 3 Acarbose versus diet and exercise, Outcome 3 Change in post-load blood glucose (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 3 Acarbose versus diet and exercise

Outcome: 3 Change in post-load blood glucose (mmol/l)

Analysis 3.4. Comparison 3 Acarbose versus diet and exercise, Outcome 4 Change in total cholesterol (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 3 Acarbose versus diet and exercise

Outcome: 4 Change in total cholesterol (mmol/l)

Analysis 3.5. Comparison 3 Acarbose versus diet and exercise, Outcome 5 Change in triglycerides (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 3 Acarbose versus diet and exercise

Outcome: 5 Change in triglycerides (mmol/l)

Analysis 3.6. Comparison 3 Acarbose versus diet and exercise, Outcome 6 Change in body mass index (Kg/m2).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 3 Acarbose versus diet and exercise

Outcome: 6 Change in body mass index (Kg/m2)

Analysis 3.7. Comparison 3 Acarbose versus diet and exercise, Outcome 7 Change in diastolic blood pressure (mmHg).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 3 Acarbose versus diet and exercise

Outcome: 7 Change in diastolic blood pressure (mmHg)

Analysis 3.8. Comparison 3 Acarbose versus diet and exercise, Outcome 8 Change in systolic blood pressure (mmHg).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 3 Acarbose versus diet and exercise

Outcome: 8 Change in systolic blood pressure (mmHg)

Analysis 4.1. Comparison 4 Acarbose versus no treatment, Outcome 1 Incidence of type 2 diabetes mellitus.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 1 Incidence of type 2 diabetes mellitus

Analysis 4.2. Comparison 4 Acarbose versus no treatment, Outcome 2 Change in fasting blood glucose (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 2 Change in fasting blood glucose (mmol/l)

Analysis 4.3. Comparison 4 Acarbose versus no treatment, Outcome 3 Change in post-load blood glucose (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 3 Change in post-load blood glucose (mmol/l)

Analysis 4.4. Comparison 4 Acarbose versus no treatment, Outcome 4 Change in total cholesterol (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 4 Change in total cholesterol (mmol/l)

Analysis 4.5. Comparison 4 Acarbose versus no treatment, Outcome 5 Change in triglycerides (mmol/l).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 5 Change in triglycerides (mmol/l)

Analysis 4.6. Comparison 4 Acarbose versus no treatment, Outcome 6 Change in body mass index (Kg/m2).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 6 Change in body mass index (Kg/m2)

Analysis 4.7. Comparison 4 Acarbose versus no treatment, Outcome 7 Change in diastolic blood pressure (mmHg).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 7 Change in diastolic blood pressure (mmHg)

Analysis 4.8. Comparison 4 Acarbose versus no treatment, Outcome 8 Change in systolic blood pressure (mmHg).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 8 Change in systolic blood pressure (mmHg)

Analysis 4.9. Comparison 4 Acarbose versus no treatment, Outcome 9 Occurrence of side effects (total).

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 9 Occurrence of side effects (total)

Analysis 4.10. Comparison 4 Acarbose versus no treatment, Outcome 10 Occurrence of gastro-intestinal side-effects.

Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

Comparison: 4 Acarbose versus no treatment

Outcome: 10 Occurrence of gastro-intestinal side-effects

ADDITIONAL TABLES

Table 1. Risk of bias

Study	Randomisation	Allocation Conceal.	Treatment Blinding	ITT analysis	Quantity drop-out	Selective drop-out	Blind outcome-assess	Analyses Blinding	Overall Quality
	A = Adequate; B = Not adequate / unclear	A = Adequate; B = Not adequate / unclear	A = adequate, B = mentioning of blinding but exact method unclear, C = non-blinded, inadequate or unknown	A = adequate, B = ITT inadequate, C = Unclear or no reported data on drop-out / loss-to-follow-up	A < 15%, B ≥ 15% or unknown	A = difference in drop-out rate in main groups < 10%, B ≥ 10% or unknown	A = adequate, B = mentioning of blinding but exact method unclear, C = non-blinded, inadequate or unknown	A = adequate, B = mentioning of blinding but exact method unclear, C = non-blinded, inadequate or unknown	A = all quality criteria met; B = one or more quality criteria only partially met; C = one or more quality criteria not met
DAISI	B	B	B	C	B	A	B	B	C
EDIT	B	B	B	C	B	B	B	B	C
Fang 2004	A	B	C	B	A	A	B	B	C
STOP-NIDDM	A	A	A	B	A	A	A	B	A
Wang 2000	B	B	C	B	A	A	B	B	C

APPENDICES

Appendix I. Search strategy

Electronic searches
<p>Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp = exploded MeSH; the asterisk (*) stands for any character(s); tw = text word; pt = publication type; sh = MeSH; adj = adjacent.</p> <p>#1 Alpha-glucosidase inhibitors (Van de Laar 2005) "Acarbose"[MeSH] OR acarbos* [tw] OR bayg5421 OR bay 5421 [tw] OR glucobay [tw] OR precos* [tw] OR prandas* [tw] OR</p>

(Continued)

akarbos* [tw] OR miglitol [tw] OR glyset [tw] OR diastabol [tw] OR baym1099 [tw] OR bay 1099 [tw] OR voglibos* [tw] OR (basen NOT basen [au]) OR emiglitat* [tw] OR alpha-glucosidase inhibitor [tw] OR glucosidase inhibitor [tw] OR alpha-glucosidase inhibitors [tw] OR glucosidase inhibitors [tw]

#2 Controlled trials (Robinson 2002)

(Randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (clinical trial [tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask* [tw] OR blind* [tw]))) OR (latin square [tw]) OR placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh])

#3 Impaired Glucose Tolerance or Impaired Fasting Blood Glucose

“Glucose Intolerance”[MeSH] OR “Diabetes Mellitus, Type II/prevention and control”[MeSH] OR “Glucose Tolerance Test”[MeSH] OR “Insulin Resistance/drug effects”[MeSH] OR “Metabolic Syndrome X”[MeSH] OR “impaired fasting glucose” [tw] OR “impaired fasting blood glucose” [tw] OR “impaired fasting bloodglucose” [tw] OR “impaired fasting glycaemia” [tw] OR “impaired fasting glycemia” [tw] OR impaired glucose toleran* [tw] OR impaired glucose stat* [tw] OR impaired glucose-respons* [tw] OR impaired glucose control* [tw] OR IGT [tw] OR glucose intoleran* [tw] OR impaired glucose regul* [tw] OR impaired glucose metab* [tw] OR impaired glucose homeost* [tw] OR reduced glucose metabolism* [tw] OR reduced glucose toleran* [tw] OR glucose intolerant* [tw] OR glucose tolerance test* [tw] OR prediabet* [tw] OR praediabet* [tw] OR “pre diabetes” [tw] OR “prae diabetes” [tw] OR “pre diabetic” [tw] OR “prae diabetic” [tw] OR “pre diabetics” [tw] OR “prae diabetics” [tw] OR metabolic syndr* [tw] OR “syndrome X” [tw] OR borderline diabet* [tw] OR mild diabet* [tw] OR insulin resistan* [tw] OR impaired insulin secret* [tw] OR reduced insulin secret* [tw]

Whole search: #1 AND #2 AND #3

These searches can be cut and pasted into PubMed (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>)

Appendix 2. Outcomes: Acarbose (ACA) versus placebo (PLA)

Outcome	STOP-NIDDM (ACA)	STOP-NIDDM (PLA)	DAISI (ACA)	DAISI (PLA)	EDIT (ACA)	EDIT (PLA)
Mortality (n/N)	Total death: 6/714; cardiovascular death: 3/714	Total death: 3/715; cardiovascular death: 2/715	No Data	No Data	No Data	No Data
Incidence of Type 2 Diabetes Mellitus (n/N)	221/682	285/686	No Data	No Data	In those with IGT at baseline, RR was reduced with acarbose (RR = 0.66, P=0.046) (at 6 years)	No Data

(Continued)

Incidence of cardiovascular morbidity (n/N)	All cardiovascular event: 15/682, myocardial infarction 1/682, angina 5/682, revascularization procedure 11/682, cardiovascular death 1/682, congestive heart failure 0/682, cerebrovascular event or stroke 2/682, peripheral vascular disease 1/682	All cardiovascular event: 32/686, myocardial infarction 12/686, angina 12/686, revascularization procedure 20/686, cardiovascular death 2/686, congestive heart failure 2/686, cerebrovascular event or stroke 4/686, peripheral vascular disease 1/686	No Data	No Data	No Data	No Data
Glycated haemoglobin (%)	Baseline (n=641) 5.24 ($\pm$ 0.74), Endpoint (n=657) 5.38 ($\pm$ 0.78), Change (n=616) 0.13 ($\pm$ 0.64)	Baseline (n=640) 5.24 ($\pm$ 0.78), Endpoint (n=667) 5.43 ($\pm$ 0.84), Change (n=622) 0.19 ($\pm$ 0.73)	No Data	No Data	No Data	No Data
Fasting blood glucose (mmol/L)	Baseline (n=682) 6.23 ($\pm$ 0.50), Endpoint (n=676) 6.27 ($\pm$ 1.17), Change (n=676) 0.05 ($\pm$ 1.14)	Baseline (n=686) 6.24 ($\pm$ 0.53), Endpoint (n=683) 6.36 ($\pm$ 1.24), Change (n=683) 0.12 ($\pm$ 1.16)	No Data	No Data	No Data	No Data
Post-load blood glucose (mmol/L)	Baseline (n=682) 9.26 ($\pm$ 1.06), Endpoint (n=656) 9.05 ($\pm$ 3.20), Change (n=656) -0.21 ($\pm$ 3.12)	Baseline (n=686) 9.25 ($\pm$ 1.01), Endpoint (n=668) 9.64 ($\pm$ 3.40), Change (n=668) 0.40 ($\pm$ 3.28)	No Data	No Data	At 3 years, compared to placebo: -0.4 mmol/L (P=0.0075) [note: half of these patients also use metformin, due to the 2x2 factorial design]	No Data
Plasma Lipids (mmol/L)	Total cholesterol: Baseline (n=648) 5.76 ($\pm$ 1.04), Endpoint (n=655) 5.64 ($\pm$ 1.04)	Total cholesterol: Baseline (n=647) 5.61 ($\pm$ 0.99), Endpoint (n=669) 5.49 ($\pm$ 0.99)	No Data	No Data	At 3 years, compared to placebo: triglycerides -0.14 mmol/L (P=0.036) [note:	No Data

(Continued)

	1.05), Change (n=621) -0.13 (± 1.00) ; HDL cholesterol: Baseline (n=645) 1.19 (± 0.32), Endpoint (n=655) 1.29 (± 0.43), Change (n=618) 0.09 (± 0.34); LDL cholesterol: Baseline (n=614) 3.66 (± 0.91), Endpoint (n=652) 3.49 (± 0.93), Change (n=587) -0.16 (± 0.87); Triglycerides: Baseline (n=649) 2.07 (± 1.10), Endpoint (n=655) 1.90 (± 1.25), Change (n=622) -0.18 (± 1.10)	1.01), Change (n=632) -0.14 (± 0.96) ; HDL cholesterol: Baseline (n=647) 1.17 (± 0.33), Endpoint (n=669) 1.24 (± 0.34), Change (n=632) 0.07 (± 0.26); LDL cholesterol: Baseline (n=618) 3.54 (± 0.90), Endpoint (n=662) 3.38 (± 0.98), Change (n=602) -0.13 (± 1.02); Triglycerides: Baseline (n=648) 2.07 (± 1.17), Endpoint (n=669) 2.01 (± 1.36), Change (n=633) -0.11 (± 0.94)			half of these patients also use metformin, due to the 2x2 factorial design] Other lipids: No data	
Blood pressure (mmHg)	Diastolic blood pressure: Baseline (n=681) 82.77 (± 9.37), Endpoint (n=677) 81.47 (± 8.75), Change (n=677) -1.31 (± 9.18); Systolic blood pressure: Baseline (n=681) 131.43 (± 16.33), Endpoint (n=677) 131.52 (± 15.42), Change (n=677) 0.03 (± 15.09)	Diastolic blood pressure: Baseline (n=686) 82.02 (± 9.29), Endpoint (n=682) 81.08 (± 9.04), Change (n=682) -0.99 (± 9.22); Systolic blood pressure: Baseline (n=686) 130.85 (± 16.21), Endpoint (n=682) 131.28 (± 15.86), Change (n=682) 0.44 (± 15.60)	No Data	No Data	No Data	No Data
Fasting and post-load insulin (pmol/L) and c-peptide (nmol/L)	Fasting insulin: Baseline (n=664) 99.93 (± 58.51), Endpoint (n=664) 97.35 (± 52.39)	Fasting insulin: Baseline (n=664) 97.35 (± 52.39), Endpoint (n=664) 97.35 (± 52.39)	No Data	No Data	No Data	No Data

(Continued)

	646) 95.64 (± 62.35), Change (n=629) -2.91 (± 58.05); Post-load insulin: Baseline (n=658) 606.37 (± 437.46), End- point (n=642) 548.95 (± 451. 19), Change (n= 620) -52.13 (± 391.43)	664) 97. 23 (± 100.89), Change (n=643) 0.65 (± 103.38); Post-load insulin: Baseline (n=657) 597.99 (± 414.38), End- point (n=661) 535.12 (± 436. 74), Change (n= 634) -64.53 (± 403.93)				
Body weight (Kg) / Body Mass Index (Kg/m2)	Body weight: Baseline (n=681) 87.63 (± 15.29) , Endpoint (n= 677) 86.95 (± 15.31), Change (n=677) -0.64 grams (± 6. 70); Body mass index: Baseline (n=682) 30.99 (± 4.30) , Endpoint (n= 677) 30.64 (± 4. 62), Change (n= 677) -0.34 (± 1. 98)	Body weight: Baseline (n=686) 87.01 (± 14.14) , Endpoint (n= 682) 87.57 (± 15.23), Change (n=682) 0.54 grams (± 5. 22); Body mass index: Baseline (n=685) 30.87 (± 4.17) , Endpoint (n= 681) 30.82 (± 4. 70), Change (n= 681) -0.03 (± 1. 94)	No Data	No Data	No Data	No Data
Adverse events (AE) (n/N)	All AEs: 698/ 714; Gastro-in- testinal AEs: 597/714	All AEs: 675/ 715; Gastro-in- testinal AEs: 426/715	No Data	No Data	No Data	No Data
Costs / Compli- ance	No Data	No Data	No Data	No Data	No Data	No Data

Appendix 3. Adjustment for high discontinuation rate in acarbose arm of STOP-NIDDM study

Outcome	Without correction	With correction
Incidence of type 2 diabetes	Effect size (OR) 0.67 (0.54 to 0.84)	Effect size (OR) 0.78 (0.63 to 0.97)
Incidence of any cardiovascular disease	Effect size (OR) 0.46 (0.25 to 0.86)	Effect size (OR) 0.52 (0.29 to 0.95)
Incidence of myocardial infarctions	Effect size (OR) 0.08 (0.01 to 0.64)	Effect size (OR) 0.08 (0.01 to 0.64)
Incidence of angina pectoris	Effect size (OR) 0.41 (0.15 to 1.18)	Effect size (OR) 0.50 (0.19 to 1.34)
Incidence of revascularization procedures	Effect size (OR) 0.55 (0.26 to 1.15)	Effect size (OR) 0.60 (0.29 to 1.23)
Incidence of congestive heart failure	Effect size (OR) 0.20 (0.01 to 4.19)	Effect size (OR) 0.20 (0.01 to 4.19)
Incidence of cerebrovascular events	Effect size (OR) 0.50 (0.09 to 2.75)	Effect size (OR) 0.50 (0.09 to 2.75)
Incidence of peripheral vascular events	Effect size (OR) 1.01 (0.06 to 16.11)	Effect size (OR) 1.01 (0.06 to 16.11)

Appendix 4. Outcomes: Acarbose (ACA) versus metformin (MET)

Outcome	EDIT (ACA)	EDIT (MET)	Fang 2004 (ACA)	Fang 2004 (MET)
Mortality (n/N)	No Data	No Data	No Data	No Data
Incidence of Type 2 Diabetes Mellitus (n/N)	No Data	No Data	6/45	9/44
Incidence of cardiovascular morbidity (n/N)	No Data	No Data	No Data	No Data
Glycated haemoglobin (%)	No Data	No Data	No Data	No Data
Fasting blood glucose (mmol/L)	No Data	No Data	Baseline (n=50) 6.45 ($\pm$ 1.9), Endpoint (n=45) 5.7 ($\pm$ 0.7), Change (n=45) -0.75 ($\pm$ 1.7)	Baseline (n=48) 6.26 ($\pm$ 2.1), Endpoint (n=44) 5.9 ($\pm$ 0.7), Change (n=44) -0.36 ($\pm$ 1.9)
Post-load blood glucose (mmol/L)	No Data	No Data	Baseline (n=50) 8.38 ($\pm$ 1.9), Endpoint (n=45) 7.0 ($\pm$ 1.8), Change (n=45) -1.38 ($\pm$ 2.0)	Baseline (n=48) 7.48 ($\pm$ 1.9), Endpoint (n=44) 7.5 ($\pm$ 1.9), Change (n=44) 0.02 ($\pm$ 2.1)
Plasma Lipids (mmol/L)	No Data	No Data	Total cholesterol: Baseline (n=50) 6.3 ($\pm$ 1.8), Endpoint (n=45) 5.6 ($\pm$ 1.7), Change (n=45) -0.7 ($\pm$ 1.9)	Total cholesterol: Baseline (n=48) 6.5 ($\pm$ 1.5), Endpoint (n=44) 4.9 ($\pm$ 1.2), Change (n=44) -1.6 ($\pm$ 1.5)

(Continued)

			; Triglycerides: Baseline (n=50) 1.9 (± 1.4), Endpoint (n=45) 1.6 (± 1.4), Change (n=45) -0.3 (± 1.5)	; Triglycerides: Baseline (n=48) 2.5 (± 2.2), Endpoint (n=44) 1.5 (± 0.5), Change (n=44) -1.0 (± 2.1)
Blood pressure (mmHg)	No Data	No Data	Diastolic blood pressure: Baseline (n=50) 82 (± 7), Endpoint (n=45) 83 (± 7), Change (n=45) 1 (± 7.67); Systolic blood pressure: Baseline (n=50) 130 (± 14), Endpoint (n=45) 124 (± 13), Change (n=45) -6 (± 14.81)	Diastolic blood pressure: Baseline (n=48) 85 (± 7), Endpoint (n=44) 80 (± 7), Change (n=44) -5 (± 7.67); Systolic blood pressure: Baseline (n=48) 132 (± 14), Endpoint (n=44) 125 (± 13), Change (n=44) -7 (± 14.81)
Fasting and post-load insulin (pmol/L) and c-peptide (nmol/L)	No Data	No Data	No Data	No Data
Body weight (Kg) / Body Mass Index (Kg/m ²)	No Data	No Data	Body mass index: Baseline (n=50) 24.9 (± 2.1), Endpoint (n=45) 24.2 (± 2.0), Change (n=45) -0.7 (± 2.25)	Body mass index: Baseline (n=48) 25.2 (± 2.8), Endpoint (n=44) 24.9 (± 2.7), Change (n=44) -0.3 (± 3.01)
Adverse events (AE) (n/N)	No Data	No Data	No Data	No Data
Costs / Compliance	No Data	No Data	No Data	No Data

Appendix 5. Outcomes: Acarbose (ACA) versus diet and exercise (DIE)

Outcome	Fang 2004 (ACA)	Fang 2004 (DIE)
Mortality (n/N)	No Data	No Data
Incidence of Type 2 Diabetes Mellitus (n/N)	6/45	12/36
Incidence of cardiovascular morbidity (n/N)	No Data	No Data
Glycated haemoglobin (%)	No Data	No Data
Fasting blood glucose (mmol/L)	Baseline (n=50) 6.45 (± 1.9), Endpoint (n=45) 5.7 (± 0.7), Change (n=45) -0.75 (± 1.7)	Baseline (n=40) 5.58 (± 2.4), Endpoint (n=36) 6.2 (± 0.6), Change (n=36) 0.62 (± 2.2)

(Continued)

Post-load blood glucose (mmol/L)	Baseline (n=50) 8.38 ($\pm$ 1.9), Endpoint (n=45) 7.0 ($\pm$ 1.8), Change (n=45) -1.38 ($\pm$ 2.0)	Baseline (n=40) 6.99 ($\pm$ 2.1), Endpoint (n=36) 8.4 ($\pm$ 2.4), Change (n=36) 1.41 ($\pm$ 2.5)
Plasma Lipids (mmol/L)	Total cholesterol: Baseline (n=50) 6.3 ($\pm$ 1.8), Endpoint (n=45) 5.6 ($\pm$ 1.7), Change (n=45) -0.7 ($\pm$ 1.9); Triglycerides: Baseline (n=50) 1.9 ($\pm$ 1.4), Endpoint (n=45) 1.6 ($\pm$ 1.4), Change (n=45) -0.3 ($\pm$ 1.5)	Total cholesterol: Baseline (n=40) 6.0 ($\pm$ 1.6), Endpoint (n=36) 5.8 ($\pm$ 1.8), Change (n=36) -0.2 ($\pm$ 1.9); Triglycerides: Baseline (n=40) 1.9 ($\pm$ 1.3), Endpoint (n=36) 1.7 ($\pm$ 1.5), Change (n=36) -0.2 ($\pm$ 1.5)
Blood pressure (mmHg)	Diastolic blood pressure: Baseline (n=50) 82 ($\pm$ 7), Endpoint (n=45) 83 ($\pm$ 7), Change (n=45) 1 ($\pm$ 7.67); Systolic blood pressure: Baseline (n=50) 130 ($\pm$ 14), Endpoint (n=45) 124 ($\pm$ 13), Change (n=45) -6 ($\pm$ 14.81)	Diastolic blood pressure: Baseline (n=40) 86 ($\pm$ 6), Endpoint (n=36) 84 ($\pm$ 6), Change (n=36) -2 ($\pm$ 6.57); Systolic blood pressure: Baseline (n=40) 126 ($\pm$ 13), Endpoint (n=36) 126 ($\pm$ 12), Change (n=36) 0 ($\pm$ 13.72)
Fasting and post-load insulin (pmol/L) and c-peptide (nmol/L)	No Data	No Data
Body weight (Kg) / Body Mass Index (Kg/m ²)	Body mass index: Baseline (n=50) 24.9 ($\pm$ 2.1), Endpoint (n=45) 24.2 ($\pm$ 2.0), Change (n=45) -0.7 ($\pm$ 2.25)	Body mass index: Baseline (n=40) 25.3 ($\pm$ 1.9), Endpoint (n=36) 24.8 ($\pm$ 1.8), Change (n=36) -0.5 ($\pm$ 2.03)
Adverse events (AE) (n/N)	No Data	No Data
Costs / Compliance	No Data	No Data

Appendix 6. Outcomes: Acarbose (ACA) versus no treatment (NO)

Outcome	Fang 2004 (ACA)	Fang 2004 (NO)	Wang 2000 (ACA)	Wang 2000 (NO)
Mortality (n/N)	No Data	No Data	No Data	No Data
Incidence of Type 2 Diabetes Mellitus (n/N)	6/45	15/35	Type 2 diabetes: 1/30, persisting IGT: 20/30, normal glucose tolerance: 9/30	Type 2 diabetes: 3/30, persisting IGT: 25/30, normal glucose tolerance: 2/30
Incidence of cardiovascular morbidity (n/N)	No Data	No Data	No Data	No Data
Glycated haemoglobin (%)	No Data	No Data	No Data	No Data

(Continued)

Fasting blood glucose (mmol/L)	Baseline (n=50) 6.45 ($\pm$ 1.9), Endpoint (n=45) 5.7 ($\pm$ 0.7), Change (n=45) -0.75 ($\pm$ 1.7)	Baseline (n=40) 5.66 ($\pm$ 2.3), Endpoint (n=35) 6.3 ($\pm$ 1.2), Change (n=35) 0.64 ($\pm$ 2.1)	No Data	No Data
Post-load blood glucose (mmol/L)	Baseline (n=50) 8.38 ($\pm$ 1.9), Endpoint (n=45) 7.0 ($\pm$ 1.8), Change (n=45) -1.38 ($\pm$ 2.0)	Baseline (n=40) 6.35 ($\pm$ 2.2), Endpoint 9.5 ($\pm$ 2.2), Change (n=35) 3.15 ($\pm$ 2.4)	No Data	No Data
Plasma Lipids (mmol/L)	Total cholesterol: Baseline (n=50) 6.3 ($\pm$ 1.8), Endpoint (n=45) 5.6 ($\pm$ 1.7), Change (n=45) -0.7 ($\pm$ 1.9); Triglycerides: Baseline (n=50) 1.9 ($\pm$ 1.4), Endpoint (n=45) 1.6 ($\pm$ 1.4), Change (n=45) -0.3 ($\pm$ 1.5)	Total cholesterol: Baseline (n=40) 5.7 ($\pm$ 1.7), Endpoint (n=35) 6.0 ($\pm$ 1.6), Change (n=35) 0.3 ($\pm$ 1.8); Triglycerides: Baseline (n=40) 1.9 ($\pm$ 1.3), Endpoint (n=35) 1.9 ($\pm$ 1.3), Change (n=35) 0.0 ($\pm$ 2.1)	No Data	No Data
Blood pressure (mmHg)	Diastolic blood pressure: Baseline (n=50) 82 ($\pm$ 7), Endpoint (n=45) 83 ($\pm$ 7), Change (n=45) 1 ($\pm$ 7.67); Systolic blood pressure: Baseline (n=50) 130 ($\pm$ 14), Endpoint (n=45) 124 ($\pm$ 13), Change (n=45) -6 ($\pm$ 14.81)	Diastolic blood pressure: Baseline (n=40) 84 ($\pm$ 6), Endpoint (n=35) 82 ($\pm$ 6), Change (n=35) -2 ($\pm$ 6.57); Systolic blood pressure: Baseline (n=40) 128 ($\pm$ 13), Endpoint (n=35) 128 ($\pm$ 12), Change (n=35) 0 ($\pm$ 13.72)	No Data	No Data
Fasting and post-load insulin (pmol/L) and c-peptide (nmol/L)	No Data	No Data	No Data	No Data
Body weight (Kg) / Body Mass Index (Kg/m ²)	Body mass index: Baseline (n=50) 24.9 ($\pm$ 2.1), Endpoint (n=45) 24.2 ($\pm$ 2.0), Change (n=45) -0.7 ($\pm$ 2.25)	Body mass index: Baseline (n=40) 24.8 ($\pm$ 2.5), Endpoint (n=35) 25.2 ($\pm$ 2.4), Change (n=35) 0.4 ($\pm$ 2.69)	No Data	No Data
Adverse events (AE) (n/N)	No Data	No Data	2/30	0/30
Costs / Compliance	No Data	No Data	No Data	No Data

WHAT'S NEW

Last assessed as up-to-date: 27 February 2006.

Date	Event	Description
30 October 2008	Amended	Converted to new review format.

HISTORY

Protocol first published: Issue 4, 2004

Review first published: Issue 4, 2006

CONTRIBUTIONS OF AUTHORS

FLORIS VAN DE LAAR: Protocol development, searching for trials, abstract assessment for eligibility, quality assessment of trials, data extraction, data entry, data analysis, review development.

PETER LUCASSEN: Protocol development, abstract assessment for eligibility, quality assessment of trials, data extraction, data analysis, review development.

WIM DE GRAUW: Protocol development, data analysis, review development.

REINIER AKKERMANS: (double) data entry, data analysis, review development.

ELOY VAN DE LISDONK: Quality assessment of trials (referee), data analysis, review development.

DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources

- Radboud University Nijmegen Medical Centre, Netherlands.

External sources

- No sources of support supplied

INDEX TERMS

Medical Subject Headings (MeSH)

Acarbose [therapeutic use]; Blood Glucose [*drug effects]; Diabetes Mellitus, Type 2 [prevention & control]; Enzyme Inhibitors [*therapeutic use]; Fasting [*blood]; Glucose Intolerance [*drug therapy]; Metformin [therapeutic use]; Prediabetic State [drug therapy]; Randomized Controlled Trials as Topic; alpha-Glucosidases [*antagonists & inhibitors]

MeSH check words

Humans